                                    PHARMACEUTICAL INSPECTION CONVENTION
                              PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME




                                                                   PE 009-17 (Part II)
                                                                   25 August 2023




          GUIDE TO GOOD MANUFACTURING
   PRACTICE FOR MEDICINAL PRODUCTS
                                       PART II


   Developed by the International Conference on Harmonisation (ICH) of
Technical Requirements for Registration of Pharmaceuticals for Human Use




                                        © PIC/S 2023
                      Reproduction prohibited for commercial purposes.
                        Reproduction for internal use is authorised,
                         provided that the source is acknowledged.




Editor:     PIC/S Secretariat
            14 rue du Roveray
            CH-1207 Geneva

e-mail:     info@picscheme.org
web site:   http://www.picscheme.org




PE 009-17 (Part II)                                                         25 August 2023
                                  TABLE OF CONTENTS
                                                                                                                        Page

1.     INTRODUCTION ............................................................................................... 1

       1.1       Objective................................................................................................ 1
       1.2       Scope .................................................................................................... 1

2.     QUALITY MANAGEMENT ................................................................................ 4

       2.1       Principles ............................................................................................... 4
       2.2       Quality Risk Management ...................................................................... 4
       2.3       Responsibilities of the Quality Unit(s)..................................................... 5
       2.4       Responsibility for Production Activities ................................................... 6
       2.5       Internal Audits (Self Inspection) ............................................................. 6
       2.6       Product Quality Review.......................................................................... 6

3.     PERSONNEL .................................................................................................... 7

       3.1       Personnel Qualifications ........................................................................ 7
       3.2       Personnel Hygiene ................................................................................ 7
       3.3       Consultants............................................................................................ 8

4.     BUILDINGS AND FACILITIES.......................................................................... 8

       4.1       Design and Construction........................................................................ 8
       4.2       Utilities ................................................................................................... 9
       4.3       Water ..................................................................................................... 9
       4.4       Containment ........................................................................................ 10
       4.5       Lighting ................................................................................................ 10
       4.6       Sewage and Refuse ............................................................................ 10
       4.7       Sanitation and Maintenance ................................................................ 10

5.     PROCESS EQUIPMENT................................................................................. 11

       5.1       Design and Construction...................................................................... 11
       5.2       Equipment Maintenance and Cleaning ................................................ 11
       5.3       Calibration ........................................................................................... 12
       5.4       Computerized Systems ........................................................................ 13


 PE 009-17 (Part II)                                       -i-                                          25 August 2023
                                                                                                 Table of contents

                                                                                                                  Page

6.     DOCUMENTATION AND RECORDS ............................................................. 14

       6.1      Documentation System and Specifications .......................................... 14
       6.2      Equipment Cleaning and Use Record .................................................. 14
       6.3      Records of Raw Materials, Intermediates, API Labelling and
                Packaging Materials ............................................................................ 15
       6.4      Master Production Instructions (Master Production and Control
                Records) .............................................................................................. 15
       6.5      Batch Production Records (Batch Production and Control
                Records) .............................................................................................. 16
       6.6      Laboratory Control Records ................................................................. 17
       6.7      Batch Production Record Review ........................................................ 17

7.     MATERIALS MANAGEMENT......................................................................... 18

       7.1      General Controls.................................................................................. 18
       7.2      Receipt and Quarantine ....................................................................... 18
       7.3      Sampling and Testing of Incoming Production Materials ...................... 19
       7.4      Storage ................................................................................................ 19
       7.5      Re-evaluation ...................................................................................... 20

8.     PRODUCTION AND IN-PROCESS CONTROLS ............................................ 20

       8.1      Production Operations ......................................................................... 20
       8.2      Time Limits .......................................................................................... 21
       8.3      In-process Sampling and Controls ....................................................... 21
       8.4      Blending Batches of Intermediates or APIs .......................................... 22
       8.5      Contamination Control ......................................................................... 22

9.     PACKAGING AND IDENTIFICATION LABELLING OF APIS AND
       INTERMEDIATES ........................................................................................... 23

       9.1      General ................................................................................................ 23
       9.2      Packaging Materials ............................................................................ 23
       9.3      Label Issuance and Control ................................................................. 23
       9.4      Packaging and Labelling Operations.................................................... 24

10.    STORAGE AND DISTRIBUTION .................................................................... 25

       10.1     Warehousing Procedures .................................................................... 25
       10.2     Distribution Procedures........................................................................ 25



 PE 009-17 (Part II)                                    - ii -                                      25 August 2023
                                                                                                  Table of contents

                                                                                                                   Page

11.    LABORATORY CONTROLS .......................................................................... 26

       11.1      General Controls.................................................................................. 26
       11.2      Testing of Intermediates and APIs ....................................................... 27
       11.3      Validation of Analytical Procedures - see Section 12. .......................... 27
       11.4      Certificates of Analysis......................................................................... 27
       11.5      Stability Monitoring of APIs .................................................................. 28
       11.6      Expiry and Retest Dating ..................................................................... 28
       11.7      Reserve/Retention Samples ................................................................ 29

12.    VALIDATION .................................................................................................. 29

       12.1      Validation Policy .................................................................................. 29
       12.2      Validation Documentation .................................................................... 30
       12.3      Qualification ......................................................................................... 30
       12.4      Approaches to Process Validation ....................................................... 30
       12.5      Process Validation Program................................................................. 31
       12.6      Periodic Review of Validated Systems ................................................. 32
       12.7      Cleaning Validation .............................................................................. 32
       12.8      Validation of Analytical Methods .......................................................... 33

13.    CHANGE CONTROL ...................................................................................... 33

14.    REJECTION AND RE-USE OF MATERIALS ................................................. 34

       14.1      Rejection.............................................................................................. 34
       14.2      Reprocessing ....................................................................................... 34
       14.3      Reworking............................................................................................ 35
       14.4      Recovery of Materials and Solvents ..................................................... 35
       14.5      Returns ................................................................................................ 35

15.    COMPLAINTS AND RECALLS ...................................................................... 36

16.    CONTRACT MANUFACTURERS (INCLUDING LABORATORIES) ............... 36

17.    AGENTS, BROKERS, TRADERS, DISTRIBUTORS, REPACKERS
       AND RELABELLERS ..................................................................................... 37

       17.1      Applicability.......................................................................................... 37
       17.2      Traceability of Distributed APIs and Intermediates ............................... 37
       17.3      Quality Management ............................................................................ 38




 PE 009-17 (Part II)                                    - iii -                                      25 August 2023
                                                                                                    Table of contents

                                                                                                                     Page

       17.4      Repackaging, Relabelling and Holding of APIs and
                 Intermediates ....................................................................................... 38
       17.5      Stability ................................................................................................ 38
       17.6      Transfer of Information......................................................................... 38
       17.7      Handling of Complaints and Recalls .................................................... 38
       17.8      Handling of Returns ............................................................................. 39

18.    SPECIFIC GUIDANCE FOR APIs MANUFACTURED BY CELL
       CULTURE/FERMENTATION .......................................................................... 39

       18.1      General ................................................................................................ 39
       18.2      Cell Bank Maintenance and Record Keeping ....................................... 40
       18.3      Cell Culture/Fermentation .................................................................... 41
       18.4      Harvesting, Isolation and Purification ................................................... 42
       18.5      Viral Removal/Inactivation Steps ......................................................... 42

19.    APIs FOR USE IN CLINICAL TRIALS ............................................................ 42

       19.1      General ................................................................................................ 42
       19.2      Quality ................................................................................................. 43
       19.3      Equipment and Facilities ...................................................................... 43
       19.4      Control of Raw Materials ...................................................................... 43
       19.5      Production ........................................................................................... 43
       19.6      Validation ............................................................................................. 44
       19.7      Changes .............................................................................................. 44
       19.8      Laboratory Controls ............................................................................. 44
       19.9      Documentation .................................................................................... 44

20.    GLOSSARY .................................................................................................... 45


                                                 ________________




 PE 009-17 (Part II)                                     - iv -                                       25 August 2023
                                                                             Introduction



1.     INTRODUCTION

1.1    Objective

This document (Guide) is intended to provide guidance regarding good manufacturing
practice (GMP) for the manufacturing of active pharmaceutical ingredients (APIs) under
an appropriate system for managing quality. It is also intended to help ensure that APIs
meet the requirements for quality and purity that they purport or are represented to
possess.

In this Guide “manufacturing” includes all operations of receipt of materials, production,
packaging, repackaging, labelling, relabelling, quality control, release, storage and
distribution of APIs and the related controls. In this Guide the term “should” indicates
recommendations that are expected to apply unless shown to be inapplicable, modified
in any relevant annexes to the GMP Guide, or replaced by an alternative demonstrated
to provide at least an equivalent level of quality assurance.

The GMP Guide as a whole does not cover safety aspects for the personnel engaged in
the manufacture, nor aspects of protection of the environment. These controls are
inherent responsibilities of the manufacturer and are governed by national laws.

This Guide is not intended to define registration requirements or modify pharmacopoeial
requirements and does not affect the ability of the responsible competent authority to
establish specific registration requirements regarding APIs within the context of
marketing/manufacturing authorisations. All commitments in registration documents
must be met.

1.2    Scope

This Guide applies to the manufacture of APIs for medicinal products for both human
and veterinary use. It applies to the manufacture of sterile APIs only up to the point
immediately prior to the APIs being rendered sterile. The sterilisation and aseptic
processing of sterile APIs are not covered, but should be performed in accordance with
the principles and guidelines of GMP as laid down in national legislations and interpreted
in the GMP Guide including its Annex 1.

In the case of ectoparasiticides for veterinary use, other standards than this Guide, that
ensure that the material is of appropriate quality, may be used.

This Guide excludes whole blood and plasma as the PIC/S GMP Guide for Blood
Establishments lays down the detailed requirements for the collection and testing of
blood. However, it does include APIs that are produced using blood or plasma as raw
materials. Finally, the Guide does not apply to bulk-packaged medicinal products. It
applies to all other active starting materials subject to any derogations described in the
annexes to the GMP Guide, in particular Annexes 2 to 7 where supplementary guidance
for certain types of API may be found. The annexes will consequently undergo a review
but in the meantime and only until this review is complete, manufacturers may choose to
continue to use Part I of the basic requirements and the relevant annexes for products
covered by those annexes, or may already apply Part II.

Section 19 contains guidance that only applies to the manufacture of APIs used in the
production of investigational medicinal products although it should be noted that its
application in this case, although recommended, is not required in PIC/S countries.



 PE 009-17 (Part II)                       -1-                            25 August 2023
                                                                                Introduction



An “API Starting Material” is a raw material, intermediate, or an API that is used in the
production of an API and that is incorporated as a significant structural fragment into the
structure of the API. An API Starting Material can be an article of commerce, a material
purchased from one or more suppliers under contract or commercial agreement, or
produced in-house. API Starting Materials normally have defined chemical properties
and structure.

The manufacturer should designate and document the rationale for the point at which
production of the API begins. For synthetic processes, this is known as the point at which
"API Starting Materials" are entered into the process. For other processes (e.g.
fermentation, extraction, purification, etc), this rationale should be established on a case-
by-case basis. Table 1 gives guidance on the point at which the API Starting Material is
normally introduced into the process.

         From this point on, appropriate GMP as defined in this Guide should be applied
       to these intermediate and/or API manufacturing steps. This would include the
       validation of critical process steps determined to impact the quality of the API.
       However, it should be noted that the fact that a manufacturer chooses to validate
       a process step does not necessarily define that step as critical.

The guidance in this document would normally be applied to the steps shown in gray in
Table 1. It does not imply that all steps shown should be completed. The stringency of
GMP in API manufacturing should increase as the process proceeds from early API steps
to final steps, purification, and packaging. Physical processing of APIs, such as
granulation, coating or physical manipulation of particle size (e.g. milling, micronizing),
should be conducted at least to the standards of this Guide.

This GMP Guide does not apply to steps prior to the introduction of the defined "API
Starting Material".




 PE 009-17 (Part II)                        -2-                             25 August 2023
                                                                                     Introduction



Table 1:    Application of this Guide to API Manufacturing



    Type of
                            Application of this Guide to steps (shown in grey) used in this type of
  Manufacturing
                                                        manufacturing

  Chemical           Production of      Introduction of   Production of     Isolation and   Physical
  Manufacturing      the API            the API           Intermediate(s)   purification    processing,
                     Starting           Starting                                            and packaging
                     Material           Material into
                                        process
  API derived        Collection of      Cutting,          Introduction of   Isolation and   Physical
  from animal        organ, fluid, or   mixing, and/or    the API           purification    processing,
  sources            tissue             initial           Starting                          and packaging
                                        processing        Material into
                                                          process
  API extracted      Collection of      Cutting and       Introduction of   Isolation and   Physical
  from plant         plant              initial           the API           purification    processing,
  sources                               extraction(s)     Starting                          and packaging
                                                          Material into
                                                          process
  Herbal extracts    Collection of      Cutting and                         Further         Physical
  used as API        plants             initial                             extraction      processing,
                                        extraction                                          and packaging
  API consisting     Collection of      Cutting/                                            Physical
  of comminuted      plants and/or      comminuting                                         processing,
  or powdered        cultivation and                                                        and packaging
  herbs              harvesting
  Biotechnology:     Establishment      Maintenance       Cell culture      Isolation and   Physical
  fermentation /     of master cell     of working cell   and/or            purification    processing,
  cell culture       bank and           bank              fermentation                      and packaging
                     working cell
                     bank
  “Classical”        Establishment      Maintenance       Introduction of   Isolation and   Physical
  Fermentation to    of cell bank       of the cell       the cells into    purification    processing,
  produce an API                        bank              fermentation                      and packaging




                             Increasing GMP requirements




      PE 009-17 (Part II)                         -3-                            25 August 2023
                                                                     Quality management



2.     QUALITY MANAGEMENT

2.1    Principles

2.10   Quality should be the responsibility of all persons involved in manufacturing.

2.11   Each manufacturer should establish, document, and implement an effective
       system for managing quality that involves the active participation of management
       and appropriate manufacturing personnel.

2.12   The system for managing quality should encompass the organisational structure,
       procedures, processes and resources, as well as activities necessary to ensure
       confidence that the API will meet its intended specifications for quality and purity.
       All quality related activities should be defined and documented.

2.13   There should be a quality unit(s) that is independent of production and that fulfils
       both quality assurance (QA) and quality control (QC) responsibilities. This can
       be in the form of separate QA and QC units or a single individual or group,
       depending upon the size and structure of the organization.

2.14   The persons authorised to release intermediates and APIs should be specified.

2.15   All quality related activities should be recorded at the time they are performed.

2.16   Any deviation from established procedures should be documented and
       explained. Critical deviations should be investigated, and the investigation and its
       conclusions should be documented.

2.17   No materials should be released or used before the satisfactory completion of
       evaluation by the quality unit(s) unless there are appropriate systems in place to
       allow for such use (e.g. release under quarantine as described in Section 10.20
       or the use of raw materials or intermediates pending completion of evaluation).

2.18   Procedures should exist for notifying responsible management in a timely manner
       of regulatory inspections, serious GMP deficiencies, product defects and related
       actions (e.g. quality related complaints, recalls, regulatory actions, etc.).

2.19   To achieve the quality objective reliably there must be a comprehensively
       designed and correctly implemented quality system incorporating Good
       Manufacturing Practice, Quality Control and Quality Risk Management.

2.2    Quality Risk Management

2.20   Quality risk management is a systematic process for the assessment, control,
       communication and review of risks to the quality of the active substance. It can
       be applied both proactively and retrospectively.

2.21   The quality risk management system should ensure that:

       -    the evaluation of the risk to quality is based on scientific knowledge,
            experience with the process and ultimately links to the protection of the
            patient through communication with the user of the active substance.



 PE 009-17 (Part II)                       -4-                             25 August 2023
                                                                      Quality management



       -     the level of effort, formality and documentation of the quality risk management
             process is commensurate with the level of risk.

       Examples of the processes and applications of quality risk management can be
       found, inter alia, in Annex 20.

2.3    Responsibilities of the Quality Unit(s)

2.30   The quality unit(s) should be involved in all quality-related matters.

2.31   The quality unit(s) should review and approve all appropriate quality-related
       documents.

2.32   The main responsibilities of the independent quality unit(s) should not be
       delegated. These responsibilities should be described in writing and should
       include but not necessarily be limited to:

       1.       Releasing or rejecting all APIs. Releasing or rejecting intermediates for
                use outside the control of the manufacturing company;

       2.       Establishing a system to release or reject raw materials, intermediates,
                packaging and labelling materials;

       3.       Reviewing completed batch production and laboratory control records of
                critical process steps before release of the API for distribution;

       4.       Making sure that critical deviations are investigated and resolved;

       5.       Approving all specifications and master production instructions;

       6.       Approving all procedures impacting the quality of intermediates or APIs;

       7.       Making sure that internal audits (self-inspections) are performed;

       8.       Approving intermediate and API contract manufacturers;

       9.       Approving changes that potentially impact intermediate or API quality;

       10.      Reviewing and approving validation protocols and reports;

       11.      Making sure that quality related complaints are investigated and resolved;

       12.      Making sure that effective systems are used for maintaining and
                calibrating critical equipment;

       13.      Making sure that materials are appropriately tested and the results are
                reported;

       14.      Making sure that there is stability data to support retest or expiry dates
                and storage conditions on APIs and/or intermediates where appropriate;
                and

       15.      Performing product quality reviews (as defined in Section 2.6).


 PE 009-17 (Part II)                        -5-                             25 August 2023
                                                                       Quality management




2.4    Responsibility for Production Activities

       The responsibility for production activities should be described in writing, and
       should include but not necessarily be limited to:

       1.       Preparing, reviewing, approving and distributing the instructions for the
                production of intermediates or APIs according to written procedures;

       2.       Producing APIs and, when appropriate, intermediates according to pre-
                approved instructions;

       3.       Reviewing all production batch records and ensuring that these are
                completed and signed;

       4.       Making sure that all production deviations are reported and evaluated and
                that critical deviations are investigated and the conclusions are recorded;

       5.       Making sure that production facilities are clean and when appropriate
                disinfected;

       6.       Making sure that the necessary calibrations are performed and records
                kept;

       7.       Making sure that the premises and equipment are maintained and records
                kept;

       8.       Making sure that validation protocols and reports are reviewed and
                approved;

       9.       Evaluating proposed changes in product, process or equipment; and

       10.      Making sure that new and, when appropriate, modified facilities and
                equipment are qualified.

2.5    Internal Audits (Self Inspection)

2.50   In order to verify compliance with the principles of GMP for APIs, regular internal
       audits should be performed in accordance with an approved schedule.

2.51   Audit findings and corrective actions should be documented and brought to the
       attention of responsible management of the firm. Agreed corrective actions
       should be completed in a timely and effective manner.

2.6    Product Quality Review

2.60   Regular quality reviews of APIs should be conducted with the objective of
       verifying the consistency of the process. Such reviews should normally be
       conducted and documented annually and should include at least:
             A review of critical in-process control and critical API test results;
             A review of all batches that failed to meet established specification(s);




 PE 009-17 (Part II)                         -6-                             25 August 2023
                                                                                  Personnel



             A review of all critical deviations or non-conformances and related
              investigations;
             A review of any changes carried out to the processes or analytical methods;
             A review of results of the stability monitoring program;
             A review of all quality-related returns, complaints and recalls; and
             A review of adequacy of corrective actions.

2.61     The result of this review should be evaluated and an assessment made of
         whether corrective action or any revalidation should be undertaken. Reasons
         for such corrective action should be documented. Agreed corrective actions
         should be completed in a timely and effective manner.

3.     PERSONNEL

3.1    Personnel Qualifications

3.10   There should be an adequate number of personnel qualified by appropriate
       education, training and/or experience to perform and supervise the manufacture
       of intermediates and APIs.

3.11   The responsibilities of all personnel engaged in the manufacture of intermediates
       and APIs should be specified in writing.

3.12   Training should be regularly conducted by qualified individuals and should cover,
       at a minimum, the particular operations that the employee performs and GMP as
       it relates to the employee's functions. Records of training should be maintained.
       Training should be periodically assessed.

3.2    Personnel Hygiene

3.20   Personnel should practice good sanitation and health habits.

3.21   Personnel should wear clean clothing suitable for the manufacturing activity with
       which they are involved and this clothing should be changed when appropriate.
       Additional protective apparel, such as head, face, hand, and arm coverings,
       should be worn when necessary, to protect intermediates and APIs from
       contamination.

3.22   Personnel should avoid direct contact with intermediates or APIs.

3.23   Smoking, eating, drinking, chewing and the storage of food should be restricted
       to certain designated areas separate from the manufacturing areas.

3.24   Personnel suffering from an infectious disease or having open lesions on the
       exposed surface of the body should not engage in activities that could result in
       compromising the quality of APIs. Any person shown at any time (either by
       medical examination or supervisory observation) to have an apparent illness or
       open lesions should be excluded from activities where the health condition could
       adversely affect the quality of the APIs until the condition is corrected or qualified




 PE 009-17 (Part II)                        -7-                             25 August 2023
                                                                    Building and facilities



       medical personnel determine that the person's inclusion would not jeopardize the
       safety or quality of the APIs.

3.3    Consultants

3.30   Consultants advising on the manufacture and control of intermediates or APIs
       should have sufficient education, training, and experience, or any combination
       thereof, to advise on the subject for which they are retained.

3.31   Records should be maintained stating the name, address, qualifications, and type
       of service provided by these consultants.


4.     BUILDINGS AND FACILITIES

4.1    Design and Construction

4.10   Buildings and facilities used in the manufacture of intermediates and APIs should
       be located, designed, and constructed to facilitate cleaning, maintenance, and
       operations as appropriate to the type and stage of manufacture. Facilities should
       also be designed to minimize potential contamination. Where microbiological
       specifications have been established for the intermediate or API, facilities should
       also be designed to limit exposure to objectionable microbiological contaminants
       as appropriate.

4.11   Buildings and facilities should have adequate space for the orderly placement of
       equipment and materials to prevent mix-ups and contamination.

4.12   Where the equipment itself (e.g., closed or contained systems) provides
       adequate protection of the material, such equipment can be located outdoors.

4.13   The flow of materials and personnel through the building or facilities should be
       designed to prevent mix-ups or contamination.

4.14   There should be defined areas or other control systems for the following activities:
        Receipt, identification, sampling, and quarantine of incoming materials,
         pending release or rejection;
        Quarantine before release or rejection of intermediates and APIs;
        Sampling of intermediates and APIs;
        Holding rejected materials         before further    disposition    (e.g.,   return,
         reprocessing or destruction);
        Storage of released materials;
        Production operations;
        Packaging and labelling operations; and
        Laboratory operations.

4.15   Adequate, clean washing and toilet facilities should be provided for personnel.
       These washing facilities should be equipped with hot and cold water as
       appropriate, soap or detergent, air driers or single service towels. The washing


 PE 009-17 (Part II)                       -8-                              25 August 2023
                                                                    Building and facilities



       and toilet facilities should be separate from, but easily accessible to,
       manufacturing areas. Adequate facilities for showering and/or changing clothes
       should be provided, when appropriate.

4.16   Laboratory areas/operations should normally be separated from production
       areas. Some laboratory areas, in particular those used for in-process controls,
       can be located in production areas, provided the operations of the production
       process do not adversely affect the accuracy of the laboratory measurements,
       and the laboratory and its operations do not adversely affect the production
       process or intermediate or API.

4.2    Utilities

4.20   All utilities that could impact on product quality (e.g. steam, gases, compressed
       air, and heating, ventilation and air conditioning) should be qualified and
       appropriately monitored and action should be taken when limits are exceeded.
       Drawings for these utility systems should be available.

4.21   Adequate ventilation, air filtration and exhaust systems should be provided,
       where appropriate. These systems should be designed and constructed to
       minimise risks of contamination and cross-contamination and should include
       equipment for control of air pressure, microorganisms (if appropriate), dust,
       humidity, and temperature, as appropriate to the stage of manufacture. Particular
       attention should be given to areas where APIs are exposed to the environment.

4.22   If air is recirculated to production areas, appropriate measures should be taken
       to control risks of contamination and cross-contamination.

4.23   Permanently installed pipework should be appropriately identified. This can be
       accomplished by identifying individual lines, documentation, computer control
       systems, or alternative means. Pipework should be located to avoid risks of
       contamination of the intermediate or API.

4.24   Drains should be of adequate size and should be provided with an air break or a
       suitable device to prevent back-siphonage, when appropriate.

4.3    Water

4.30   Water used in the manufacture of APIs should be demonstrated to be suitable for
       its intended use.

4.31   Unless otherwise justified, process water should, at a minimum, meet World
       Health Organization (WHO) guidelines for drinking (potable) water quality.

4.32   If drinking (potable) water is insufficient to assure API quality, and tighter
       chemical and/or microbiological water quality specifications are called for,
       appropriate specifications for physical/chemical attributes, total microbial counts,
       objectionable organisms and/or endotoxins should be established.

4.33   Where water used in the process is treated by the manufacturer to achieve a
       defined quality, the treatment process should be validated and monitored with
       appropriate action limits.



 PE 009-17 (Part II)                       -9-                            25 August 2023
                                                                     Building and facilities



4.34   Where the manufacturer of a non-sterile API either intends or claims that it is
       suitable for use in further processing to produce a sterile drug (medicinal)
       product, water used in the final isolation and purification steps should be
       monitored and controlled for total microbial counts, objectionable organisms, and
       endotoxins.

4.4    Containment

4.40   Dedicated production areas, which can include facilities, air handling equipment
       and/or process equipment, should be employed in the production of highly
       sensitizing materials, such as penicillins or cephalosporins.

4.41   Dedicated production areas should also be considered when material of an
       infectious nature or high pharmacological activity or toxicity is involved (e.g.,
       certain steroids or cytotoxic anti-cancer agents) unless validated inactivation
       and/or cleaning procedures are established and maintained.

4.42   Appropriate measures should be established and implemented to prevent cross-
       contamination from personnel, materials, etc. moving from one dedicated area to
       another.

4.43   Any production activities (including weighing, milling, or packaging) of highly toxic
       non-pharmaceutical materials such as herbicides and pesticides should not be
       conducted using the buildings and/or equipment being used for the production of
       APIs. Handling and storage of these highly toxic non-pharmaceutical materials
       should be separate from APIs.

4.5    Lighting

4.50   Adequate lighting should be provided in all areas to facilitate cleaning,
       maintenance, and proper operations.

4.6    Sewage and Refuse

4.60   Sewage, refuse, and other waste (e.g., solids, liquids, or gaseous by-products
       from manufacturing) in and from buildings and the immediate surrounding area
       should be disposed of in a safe, timely, and sanitary manner. Containers and/or
       pipes for waste material should be clearly identified.

4.7    Sanitation and Maintenance

4.70   Buildings used in the manufacture of intermediates and APIs should be properly
       maintained and repaired and kept in a clean condition.

4.71   Written procedures should be established assigning responsibility for sanitation
       and describing the cleaning schedules, methods, equipment, and materials to be
       used in cleaning buildings and facilities.




 PE 009-17 (Part II)                       - 10 -                          25 August 2023
                                                                       Process Equipment




4.72   When necessary, written procedures should also be established for the use of
       suitable rodenticides, insecticides, fungicides, fumigating agents, and cleaning
       and sanitizing agents to prevent the contamination of equipment, raw materials,
       packaging/labelling materials, intermediates, and APIs.


5.     PROCESS EQUIPMENT

5.1    Design and Construction

5.10   Equipment used in the manufacture of intermediates and APIs should be of
       appropriate design and adequate size, and suitably located for its intended use,
       cleaning, sanitization (where appropriate), and maintenance.

5.11   Equipment should be constructed so that surfaces that contact raw materials,
       intermediates, or APIs do not alter the quality of the intermediates and APIs
       beyond the official or other established specifications.

5.12   Production equipment should only be used within its qualified operating range.

5.13   Major equipment (e.g., reactors, storage containers) and permanently installed
       processing lines used during the production of an intermediate or API should be
       appropriately identified.

5.14   Any substances associated with the operation of equipment, such as lubricants,
       heating fluids or coolants, should not contact intermediates or APIs so as to alter
       their quality beyond the official or other established specifications. Any deviations
       from this should be evaluated to ensure that there are no detrimental effects upon
       the fitness for purpose of the material. Wherever possible, food grade lubricants
       and oils should be used.

5.15   Closed or contained equipment should be used whenever appropriate. Where
       open equipment is used, or equipment is opened, appropriate precautions should
       be taken to minimize the risk of contamination.

5.16   A set of current drawings should be maintained for equipment and critical
       installations (e.g., instrumentation and utility systems).

5.2    Equipment Maintenance and Cleaning

5.20   Schedules and procedures (including assignment of responsibility) should be
       established for the preventative maintenance of equipment.

5.21   Written procedures should be established for cleaning of equipment and its
       subsequent release for use in the manufacture of intermediates and APIs.
       Cleaning procedures should contain sufficient details to enable operators to clean
       each type of equipment in a reproducible and effective manner. These
       procedures should include:
             Assignment of responsibility for cleaning of equipment;
             Cleaning schedules, including, where appropriate, sanitizing schedules;



 PE 009-17 (Part II)                       - 11 -                          25 August 2023
                                                                        Process Equipment



             A complete description of the methods and materials, including dilution of
              cleaning agents used to clean equipment;
             When appropriate, instructions for disassembling and reassembling each
              article of equipment to ensure proper cleaning;
             Instructions for the removal or obliteration of previous batch identification;
             Instructions for the protection of clean equipment from contamination prior
              to use;
             Inspection of equipment for cleanliness immediately before use, if practical;
              and
             Establishing the maximum time that may elapse between the completion of
              processing and equipment cleaning, when appropriate.

5.22   Equipment and utensils should be cleaned, stored, and, where appropriate,
       sanitized or sterilized to prevent contamination or carry-over of a material that
       would alter the quality of the intermediate or API beyond the official or other
       established specifications.

5.23   Where equipment is assigned to continuous production or campaign production
       of successive batches of the same intermediate or API, equipment should be
       cleaned at appropriate intervals to prevent build-up and carry-over of
       contaminants (e.g. degradants or objectionable levels of micro-organisms).

5.24   Non-dedicated equipment should be cleaned between production of different
       materials to prevent cross-contamination.

5.25   Acceptance criteria for residues and the choice of cleaning procedures and
       cleaning agents should be defined and justified.

5.26   Equipment should be identified as to its contents and its cleanliness status by
       appropriate means.

5.3    Calibration

5.30   Control, weighing, measuring, monitoring and test equipment that is critical for
       assuring the quality of intermediates or APIs should be calibrated according to
       written procedures and an established schedule.

5.31   Equipment calibrations should be performed using standards traceable to
       certified standards, if existing.

5.32   Records of these calibrations should be maintained.

5.33   The current calibration status of critical equipment should be known and
       verifiable.

5.34   Instruments that do not meet calibration criteria should not be used.

5.35   Deviations from approved standards of calibration on critical instruments should
       be investigated to determine if these could have had an impact on the quality of




 PE 009-17 (Part II)                       - 12 -                           25 August 2023
                                                                Computerized systems



the intermediate(s) or API(s) manufactured using this equipment since the last
       successful calibration.

5.4    Computerized Systems

5.40   GMP related computerized systems should be validated. The depth and scope
       of validation depends on the diversity, complexity and criticality of the
       computerized application.

5.41   Appropriate installation qualification and operational qualification should
       demonstrate the suitability of computer hardware and software to perform
       assigned tasks.

5.42   Commercially available software that has been qualified does not require the
       same level of testing. If an existing system was not validated at time of
       installation, a retrospective validation could be conducted if appropriate
       documentation is available.

5.43   Computerized systems should have sufficient controls to prevent unauthorized
       access or changes to data. There should be controls to prevent omissions in data
       (e.g. system turned off and data not captured). There should be a record of any
       data change made, the previous entry, who made the change, and when the
       change was made.

5.44   Written procedures should be available for the operation and maintenance of
       computerized systems.

5.45   Where critical data are being entered manually, there should be an additional
       check on the accuracy of the entry. This can be done by a second operator or
       by the system itself.

5.46   Incidents related to computerized systems that could affect the quality of
       intermediates or APIs or the reliability of records or test results should be
       recorded and investigated.

5.47   Changes to the computerized system should be made according to a change
       procedure and should be formally authorized, documented and tested. Records
       should be kept of all changes, including modifications and enhancements made
       to the hardware, software and any other critical component of the system. These
       records should demonstrate that the system is maintained in a validated state.

5.48   If system breakdowns or failures would result in the permanent loss of records, a
       back-up system should be provided. A means of ensuring data protection should
       be established for all computerized systems.

5.49   Data can be recorded by a second means in addition to the computer system.




 PE 009-17 (Part II)                     - 13 -                         25 August 2023
                                                            Documentation and Records



6.     DOCUMENTATION AND RECORDS

6.1    Documentation System and Specifications

6.10   All documents related to the manufacture of intermediates or APIs should be
       prepared, reviewed, approved and distributed according to written procedures.
       Such documents can be in paper or electronic form.

6.11   The issuance, revision, superseding and withdrawal of all documents should be
       controlled with maintenance of revision histories.

6.12   A procedure should be established for retaining all appropriate documents (e.g.,
       development history reports, scale-up reports, technical transfer reports, process
       validation reports, training records, production records, control records, and
       distribution records). The retention periods for these documents should be
       specified.

6.13   All production, control, and distribution records should be retained for at least 1
       year after the expiry date of the batch. For APIs with retest dates, records should
       be retained for at least 3 years after the batch is completely distributed.

6.14   When entries are made in records, these should be made indelibly in spaces
       provided for such entries, directly after performing the activities, and should
       identify the person making the entry. Corrections to entries should be dated and
       signed and leave the original entry still readable.

6.15   During the retention period, originals or copies of records should be readily
       available at the establishment where the activities described in such records
       occurred. Records that can be promptly retrieved from another location by
       electronic or other means are acceptable.

6.16   Specifications, instructions, procedures, and records can be retained either as
       originals or as true copies such as photocopies, microfilm, microfiche, or other
       accurate reproductions of the original records. Where reduction techniques such
       as microfilming or electronic records are used, suitable retrieval equipment and
       a means to produce a hard copy should be readily available.

6.17   Specifications should be established and documented for raw materials,
       intermediates where necessary, APIs, and labelling and packaging materials. In
       addition, specifications may be appropriate for certain other materials, such as
       process aids, gaskets, or other materials used during the production of
       intermediates or APIs that could critically impact on quality. Acceptance criteria
       should be established and documented for in-process controls.

6.18   If electronic signatures are used on documents, they should be authenticated and
       secure.

6.2    Equipment Cleaning and Use Record

6.20   Records of major equipment use, cleaning, sanitization and/or sterilization and
       maintenance should show the date, time (if appropriate), product, and batch
       number of each batch processed in the equipment, and the person who
       performed the cleaning and maintenance.


 PE 009-17 (Part II)                      - 14 -                         25 August 2023
                                                             Documentation and Records




6.21   If equipment is dedicated to manufacturing one intermediate or API, then
       individual equipment records are not necessary if batches of the intermediate or
       API follow in traceable sequence. In cases where dedicated equipment is
       employed, the records of cleaning, maintenance, and use can be part of the batch
       record or maintained separately.

6.3    Records of Raw Materials, Intermediates, API Labelling and Packaging
       Materials

6.30   Records should be maintained including:
             The name of the manufacturer, identity and quantity of each shipment of
              each batch of raw materials, intermediates or labelling and packaging
              materials for API's; the name of the supplier; the supplier's control
              number(s), if known, or other identification number; the number allocated
              on receipt; and the date of receipt;
             The results of any test or examination performed and the conclusions
              derived from this;
             Records tracing the use of materials;
             Documentation of the examination and review of API labelling and
              packaging materials for conformity with established specifications; and
             The final decision regarding rejected raw materials, intermediates or API
              labelling and packaging materials.

6.31   Master (approved) labels should be maintained for comparison to issued labels.

6.4    Master Production Instructions (Master Production and Control Records)

6.40   To ensure uniformity from batch to batch, master production instructions for each
       intermediate and API should be prepared, dated, and signed by one person and
       independently checked, dated, and signed by a person in the quality unit(s).

6.41   Master production instructions should include:
             The name of the intermediate or API being manufactured and an identifying
              document reference code, if applicable;
             A complete list of raw materials and intermediates designated by names or
              codes sufficiently specific to identify any special quality characteristics;
             An accurate statement of the quantity or ratio of each raw material or
              intermediate to be used, including the unit of measure. Where the quantity
              is not fixed, the calculation for each batch size or rate of production should
              be included. Variations to quantities should be provided they are justified;
             The production location and major production equipment to be used;
             Detailed production instructions, including the:
              -   sequences to be followed,
              -   ranges of process parameters to be used,




 PE 009-17 (Part II)                       - 15 -                          25 August 2023
                                                              Documentation and Records



              -   sampling instructions and in-process controls with their acceptance
                  criteria, where appropriate,
              -   time limits for completion of individual processing steps and/or the total
                  process, where appropiate; and
              -   expected yield ranges at appropriate phases of processing or time;
             Where appropriate, special notations and precautions to be followed, or
              cross-references to these; and
             The instructions for storage of the intermediate or API to assure its
              suitability for use, including the labelling and packaging materials and
              special storage conditions with time limits, where appropriate.

6.5    Batch Production Records (Batch Production and Control Records)

6.50   Batch production records should be prepared for each intermediate and API and
       should include complete information relating to the production and control of each
       batch. The batch production record should be checked before issuance to assure
       that it is the correct version and a legible accurate reproduction of the appropriate
       master production instruction. If the batch production record is produced from a
       separate part of the master document, that document should include a reference
       to the current master production instruction being used.

6.51   These records should be numbered with a unique batch or identification number,
       dated and signed when issued. In continuous production, the product code
       together with the date and time can serve as the unique identifier until the final
       number is allocated.

6.52   Documentation of completion of each significant step in the batch production
       records (batch production and control records) should include:
             Dates and, when appropriate, times;
             Identity of major equipment (e.g., reactors, driers, mills, etc.) used;
             Specific identification of each batch, including weights, measures, and
              batch numbers of raw materials, intermediates, or any reprocessed
              materials used during manufacturing;
             Actual results recorded for critical process parameters;
             Any sampling performed;
             Signatures of the persons performing and directly supervising or checking
              each critical step in the operation;
             In-process and laboratory test results;
             Actual yield at appropriate phases or times;
             Description of packaging and label for intermediate or API;
             Representative label of API or intermediate if made commercially available;
             Any deviation noted, its evaluation, investigation conducted (if appropriate)
              or reference to that investigation if stored separately; and
             Results of release testing.




 PE 009-17 (Part II)                        - 16 -                          25 August 2023
                                                             Documentation and Records



6.53   Written procedures should be established and followed for investigating critical
       deviations or the failure of a batch of intermediate or API to meet specifications.
       The investigation should extend to other batches that may have been associated
       with the specific failure or deviation.

6.6    Laboratory Control Records

6.60   Laboratory control records should include complete data derived from all tests
       conducted to ensure compliance with established specifications and standards,
       including examinations and assays, as follows:
             A description of samples received for testing, including the material name
              or source, batch number or other distinctive code, date sample was taken,
              and, where appropriate, the quantity and date the sample was received for
              testing;
             A statement of or reference to each test method used;
             A statement of the weight or measure of sample used for each test as
              described by the method; data on or cross-reference to the preparation and
              testing of reference standards, reagents and standard solutions,
             A complete record of all raw data generated during each test, in addition to
              graphs, charts, and spectra from laboratory instrumentation, properly
              identified to show the specific material and batch tested;
             A record of all calculations performed in connection with the test, including,
              for example, units of measure, conversion factors, and equivalency factors;
             A statement of the test results and how they compare with established
              acceptance criteria;
             The signature of the person who performed each test and the date(s) the
              tests were performed; and
             The date and signature of a second person showing that the original
              records have been reviewed for accuracy, completeness, and compliance
              with established standards.

6.61   Complete records should also be maintained for:
             Any modifications to an established analytical method,
             Periodic calibration of laboratory instruments, apparatus, gauges, and
              recording devices;
             All stability testing performed on APIs; and
             Out-of-specification (OOS) investigations.

6.7    Batch Production Record Review

6.70   Written procedures should be established and followed for the review and
       approval of batch production and laboratory control records, including
        packaging and labelling, to determine compliance of the intermediate or API with
       established specifications before a batch is released or distributed.

6.71   Batch production and laboratory control records of critical process steps should
       be reviewed and approved by the quality unit(s) before an API batch is released
       or distributed. Production and laboratory control records of non-critical process


 PE 009-17 (Part II)                       - 17 -                          25 August 2023
                                                                    Materials Management



       steps can be reviewed by qualified production personnel or other units following
       procedures approved by the quality unit(s).

6.72   All deviation, investigation, and OOS reports should be reviewed as part of the
       batch record review before the batch is released.

6.73   The quality unit(s) can delegate to the production unit the responsibility and
       authority for release of intermediates, except for those shipped outside the control
       of the manufacturing company.


7.     MATERIALS MANAGEMENT

7.1    General Controls

7.10   There should be written procedures describing the receipt, identification,
       quarantine, storage, handling, sampling, testing, and approval or rejection of
       materials.

7.11   Manufacturers of intermediates and/or APIs should have a system for evaluating
       the suppliers of critical materials.

7.12   Materials should be purchased against an agreed specification, from a supplier
       or suppliers approved by the quality unit(s).

7.13   If the supplier of a critical material is not the manufacturer of that material, the
       name and address of that manufacturer should be known by the intermediate
       and/or API manufacturer.

7.14   Changing the source of supply of critical raw materials should be treated
       according to Section 13, Change Control.

7.2    Receipt and Quarantine

7.20   Upon receipt and before acceptance, each container or grouping of containers of
       materials should be examined visually for correct labelling (including correlation
       between the name used by the supplier and the in-house name, if these are
       different), container damage, broken seals and evidence of tampering or
       contamination. Materials should be held under quarantine until they have been
       sampled, examined or tested as appropriate, and released for use.

7.21   Before incoming materials are mixed with existing stocks (e.g., solvents or stocks
       in silos), they should be identified as correct, tested, if appropriate, and released.
       Procedures should be available to prevent discharging incoming materials
       wrongly into the existing stock.

7.22   If bulk deliveries are made in non-dedicated tankers, there should be assurance
       of no cross-contamination from the tanker. Means of providing this assurance
       could include one or more of the following:
             certificate of cleaning
             testing for trace impurities



 PE 009-17 (Part II)                         - 18 -                         25 August 2023
                                                                     Materials Management



             audit of the supplier.

7.23   Large storage containers, and their attendant manifolds, filling and discharge
       lines should be appropriately identified.

7.24   Each container or grouping of containers (batches) of materials should be
       assigned and identified with a distinctive code, batch, or receipt number. This
       number should be used in recording the disposition of each batch. A system
       should be in place to identify the status of each batch.

7.3    Sampling and Testing of Incoming Production Materials

7.30   At least one test to verify the identity of each batch of material should be
       conducted, with the exception of the materials described below in 7.32. A
       supplier's Certificate of Analysis can be used in place of performing other tests,
       provided that the manufacturer has a system in place to evaluate suppliers.

7.31   Supplier approval should include an evaluation that provides adequate evidence
       (e.g., past quality history) that the manufacturer can consistently provide material
       meeting specifications. Full analyses should be conducted on at least three
       batches before reducing in-house testing. However, as a minimum, a full analysis
       should be performed at appropriate intervals and compared with the Certificates
       of Analysis. Reliability of Certificates of Analysis should be checked at regular
       intervals.

7.32   Processing aids, hazardous or highly toxic raw materials, other special materials,
       or materials transferred to another unit within the company’s control do not need
       to be tested if the manufacturer’s Certificate of Analysis is obtained, showing that
       these raw materials conform to established specifications. Visual examination of
       containers, labels, and recording of batch numbers should help in establishing
       the identity of these materials. The lack of on-site testing for these materials
       should be justified and documented.

7.33   Samples should be representative of the batch of material from which they are
       taken. Sampling methods should specify the number of containers to be
       sampled, which part of the container to sample, and the amount of material to be
       taken from each container. The number of containers to sample and the sample
       size should be based upon a sampling plan that takes into consideration the
       criticality of the material, material variability, past quality history of the supplier,
       and the quantity needed for analysis.

7.34   Sampling should be conducted at defined locations and by procedures designed
       to prevent contamination of the material sampled and contamination of other
       materials.

7.35   Containers from which samples are withdrawn should be opened carefully and
       subsequently reclosed. They should be marked to indicate that a sample has
       been taken.

7.4    Storage

7.40   Materials should be handled and stored in a manner to prevent degradation,
       contamination, and cross-contamination.


 PE 009-17 (Part II)                        - 19 -                           25 August 2023
                                                      Production and In-Process Controls




7.41   Materials stored in fiber drums, bags, or boxes should be stored off the floor and,
       when appropriate, suitably spaced to permit cleaning and inspection.

7.42   Materials should be stored under conditions and for a period that have no adverse
       affect on their quality, and should normally be controlled so that the oldest stock
       is used first.

7.43   Certain materials in suitable containers can be stored outdoors, provided
       identifying labels remain legible and containers are appropriately cleaned before
       opening and use.

7.44   Rejected materials should be identified and controlled under a quarantine system
       designed to prevent their unauthorised use in manufacturing.

7.5    Re-evaluation

7.50   Materials should be re-evaluated as appropriate to determine their suitability for
       use (e.g., after prolonged storage or exposure to heat or humidity).


8.     PRODUCTION AND IN-PROCESS CONTROLS

8.1    Production Operations

8.10   Raw materials for intermediate and API manufacturing should be weighed or
       measured under appropriate conditions that do not affect their suitability for use.
       Weighing and measuring devices should be of suitable accuracy for the intended
       use.

8.11   If a material is subdivided for later use in production operations, the container
       receiving the material should be suitable and should be so identified that the
       following information is available:
             Material name and/or item code;
             Receiving or control number;
             Weight or measure of material in the new container; and
             Re-evaluation or retest date if appropriate.

8.12   Critical weighing, measuring, or subdividing operations should be witnessed or
       subjected to an equivalent control. Prior to use, production personnel should
       verify that the materials are those specified in the batch record for the intended
       intermediate or API.

8.13   Other critical activities should be witnessed or subjected to an equivalent control.

8.14   Actual yields should be compared with expected yields at designated steps in the
       production process. Expected yields with appropriate ranges should be
       established based on previous laboratory, pilot scale, or manufacturing data.
       Deviations in yield associated with critical process steps should be investigated
       to determine their impact or potential impact on the resulting quality of affected
       batches.


 PE 009-17 (Part II)                       - 20 -                         25 August 2023
                                                      Production and In-Process Controls




8.15   Any deviation should be documented and explained. Any critical deviation should
       be investigated.

8.16   The processing status of major units of equipment should be indicated either on
       the individual units of equipment or by appropriate documentation, computer
       control systems, or alternative means.

8.17   Materials to be reprocessed or reworked should be appropriately controlled to
       prevent unauthorized use.

8.2    Time Limits

8.20   If time limits are specified in the master production instruction (see 6.41), these
       time limits should be met to ensure the quality of intermediates and APIs.
       Deviations should be documented and evaluated. Time limits may be
       inappropriate when processing to a target value (e.g., pH adjustment,
       hydrogenation, drying to predetermined specification) because completion of
       reactions or processing steps are determined by in-process sampling and testing.

8.21   Intermediates held for further processing should be stored under appropriate
       conditions to ensure their suitability for use.

8.3    In-process Sampling and Controls

8.30   Written procedures should be established to monitor the progress and control the
       performance of processing steps that cause variability in the quality
       characteristics of intermediates and APIs. In-process controls and their
       acceptance criteria should be defined based on the information gained during the
       development stage or historical data.

8.31   The acceptance criteria and type and extent of testing can depend on the nature
       of the intermediate or API being manufactured, the reaction or process step being
       conducted, and the degree to which the process introduces variability in the
       product’s quality. Less stringent in-process controls may be appropriate in early
       processing steps, whereas tighter controls may be appropriate for later
       processing steps (e.g., isolation and purification steps).

8.32   Critical in-process controls (and critical process monitoring), including the control
       points and methods, should be stated in writing and approved by the quality
       unit(s).

8.33   In-process controls can be performed by qualified production department
       personnel and the process adjusted without prior quality unit(s) approval if the
       adjustments are made within pre-established limits approved by the quality
       unit(s). All tests and results should be fully documented as part of the batch
       record.

8.34   Written procedures should describe the sampling methods for in-process
       materials, intermediates, and APIs. Sampling plans and procedures should be
       based on scientifically sound sampling practices.




 PE 009-17 (Part II)                       - 21 -                          25 August 2023
                                                        Production and In-Process Controls



8.35   In-process sampling should be conducted using procedures designed to prevent
       contamination of the sampled material and other intermediates or APIs.
       Procedures should be established to ensure the integrity of samples after
       collection.

8.36   Out-of-specification (OOS) investigations are not normally needed for in-process
       tests that are performed for the purpose of monitoring and/or adjusting the
       process.

8.4    Blending Batches of Intermediates or APIs

8.40   For the purpose of this document, blending is defined as the process of combining
       materials within the same specification to produce a homogeneous intermediate
       or API. In-process mixing of fractions from single batches (e.g., collecting
       several centrifuge loads from a single crystallization batch) or combining fractions
       from several batches for further processing is considered to be part of the
       production process and is not considered to be blending.

8.41   Out-Of-Specification batches should not be blended with other batches for the
       purpose of meeting specifications. Each batch incorporated into the blend should
       have been manufactured using an established process and should have been
       individually tested and found to meet appropriate specifications prior to blending.

8.42   Acceptable blending operations include but are not limited to:
             Blending of small batches to increase batch size
             Blending of tailings (i.e., relatively small quantities of isolated material) from
              batches of the same intermediate or API to form a single batch.

8.43   Blending processes should be adequately controlled and documented and the
       blended batch should be tested for conformance to established specifications
       where appropriate.

8.44   The batch record of the blending process should allow traceability back to the
       individual batches that make up the blend.

8.45   Where physical attributes of the API are critical (e.g., APIs intended for use in
       solid oral dosage forms or suspensions), blending operations should be validated
       to show homogeneity of the combined batch. Validation should include testing
       of critical attributes (e.g., particle size distribution, bulk density, and tap density)
       that may be affected by the blending process.

8.46   If the blending could adversely affect stability, stability testing of the final blended
       batches should be performed.

8.47   The expiry or retest date of the blended batch should be based on the
       manufacturing date of the oldest tailings or batch in the blend.

8.5    Contamination Control

8.50   Residual materials can be carried over into successive batches of the same
       intermediate or API if there is adequate control. Examples include residue
       adhering to the wall of a micronizer, residual layer of damp crystals remaining in



 PE 009-17 (Part II)                         - 22 -                           25 August 2023
                       Packaging and Identification Labelling of APIs and Intermediates



       a centrifuge bowl after discharge, and incomplete discharge of fluids or crystals
       from a processing vessel upon transfer of the material to the next step in the
       process. Such carryover should not result in the carryover of degradants or
       microbial contamination that may adversely alter the established API impurity
       profile.

8.51   Production operations should be conducted in a manner that will prevent
       contamination of intermediates or APIs by other materials.

8.52   Precautions to avoid contamination should be taken when APIs are handled after
       purification.


9.     PACKAGING AND IDENTIFICATION LABELLING OF APIS AND
       INTERMEDIATES

9.1    General

9.10   There should be written procedures describing the receipt, identification,
       quarantine, sampling, examination and/or testing and release, and handling of
       packaging and labelling materials.

9.11   Packaging and labelling materials should conform to established specifications.
       Those that do not comply with such specifications should be rejected to prevent
       their use in operations for which they are unsuitable.

9.12   Records should be maintained for each shipment of labels and packaging
       materials showing receipt, examination, or testing, and whether accepted or
       rejected.

9.2    Packaging Materials

9.20   Containers should provide adequate protection against deterioration or
       contamination of the intermediate or API that may occur during transportation and
       recommended storage.

9.21   Containers should be clean and, where indicated by the nature of the
       intermediate or API, sanitized to ensure that they are suitable for their intended
       use. These containers should not be reactive, additive, or absorptive so as to
       alter the quality of the intermediate or API beyond the specified limits.

9.22   If containers are re-used, they should be cleaned in accordance with documented
       procedures and all previous labels should be removed or defaced.

9.3    Label Issuance and Control

9.30   Access to the label storage areas should be limited to authorised personnel.

9.31   Procedures should be used to reconcile the quantities of labels issued, used, and
       returned and to evaluate discrepancies found between the number of containers
       labelled and the number of labels issued. Such discrepancies should be
       investigated, and the investigation should be approved by the quality unit(s).




 PE 009-17 (Part II)                     - 23 -                          25 August 2023
                       Packaging and Identification Labelling of APIs and Intermediates



9.32   All excess labels bearing batch numbers or other batch-related printing should
       be destroyed. Returned labels should be maintained and stored in a manner that
       prevents mix-ups and provides proper identification.

9.33   Obsolete and out-dated labels should be destroyed.

9.34   Printing devices used to print labels for packaging operations should be
       controlled to ensure that all imprinting conforms to the print specified in the batch
       production record.

9.35   Printed labels issued for a batch should be carefully examined for proper identity
       and conformity to specifications in the master production record. The results of
       this examination should be documented.

9.36   A printed label representative of those used should be included in the batch
       production record.

9.4    Packaging and Labelling Operations

9.40   There should be documented procedures designed to ensure that correct
       packaging materials and labels are used.

9.41   Labelling operations should be designed to prevent mix-ups. There should be
       physical or spatial separation from operations involving other intermediates or
       APIs.

9.42   Labels used on containers of intermediates or APIs should indicate the name or
       identifying code, the batch number of the product, and storage conditions, when
       such information is critical to assure the quality of intermediate or API.

9.43   If the intermediate or API is intended to be transferred outside the control of the
       manufacturer’s material management system, the name and address of the
       manufacturer, quantity of contents, and special transport conditions and any
       special legal requirements should also be included on the label.                For
       intermediates or APIs with an expiry date, the expiry date should be indicated on
       the label and Certificate of Analysis. For intermediates or APIs with a retest date,
       the retest date should be indicated on the label and/or Certificate of Analysis.

9.44   Packaging and labelling facilities should be inspected immediately before use to
       ensure that all materials not needed for the next packaging operation have been
       removed. This examination should be documented in the batch production
       records, the facility log, or other documentation system.

9.45   Packaged and labelled intermediates or APIs should be examined to ensure that
       containers and packages in the batch have the correct label. This examination
       should be part of the packaging operation. Results of these examinations should
       be recorded in the batch production or control records.

9.46   Intermediate or API containers that are transported outside of the manufacturer's
       control should be sealed in a manner such that, if the seal is breached or missing,
       the recipient will be alerted to the possibility that the contents may have been
       altered.



 PE 009-17 (Part II)                       - 24 -                          25 August 2023
                                                                Storage and Distribution




10.    STORAGE AND DISTRIBUTION

10.1   Warehousing Procedures

10.10 Facilities should be available for the storage of all materials under appropriate
      conditions (e.g. controlled temperature and humidity when necessary). Records
      should be maintained of these conditions if they are critical for the maintenance
      of material characteristics.

10.11 Unless there is an alternative system to prevent the unintentional or unauthorised
      use of quarantined, rejected, returned, or recalled materials, separate storage
      areas should be assigned for their temporary storage until the decision as to their
      future use has been taken.

10.2   Distribution Procedures

10.20 APIs and intermediates should only be released for distribution to third parties
      after they have been released by the quality unit(s). APIs and intermediates can
      be transferred under quarantine to another unit under the company’s control
      when authorized by the quality unit(s) and if appropriate controls and
      documentation are in place.

10.21 APIs and intermediates should be transported in a manner that does not
      adversely affect their quality.

10.22 Special transport or storage conditions for an API or intermediate should be
      stated on the label.

10.23 The manufacturer should ensure that the contract acceptor (contractor) for
      transportation of the API or intermediate knows and follows the appropriate
      transport and storage conditions.

10.24 A system should be in place by which the distribution of each batch of
      intermediate and/or API can be readily determined to permit its recall.




 PE 009-17 (Part II)                      - 25 -                         25 August 2023
                                                                      Laboratory Controls



11.    LABORATORY CONTROLS

11.1   General Controls

11.10 The independent quality unit(s) should have at its disposal adequate laboratory
      facilities.

11.11 There should be documented procedures describing sampling, testing, approval
      or rejection of materials, and recording and storage of laboratory data.
      Laboratory records should be maintained in accordance with Section 6.6.

11.12 All specifications, sampling plans, and test procedures should be scientifically
      sound and appropriate to ensure that raw materials, intermediates, APIs, and
      labels and packaging materials conform to established standards of quality
      and/or purity. Specifications and test procedures should be consistent with those
      included in the registration/filing. There can be specifications in addition to those
      in the registration/filing. Specifications, sampling plans, and test procedures,
      including changes to them, should be drafted by the appropriate organizational
      unit and reviewed and approved by the quality unit(s).

11.13 Appropriate specifications should be established for APIs in accordance with
      accepted standards and consistent with the manufacturing process. The
      specifications should include a control of the impurities (e.g. organic impurities,
      inorganic impurities, and residual solvents). If the API has a specification for
      microbiological purity, appropriate action limits for total microbial counts and
      objectionable organisms should be established and met. If the API has a
      specification for endotoxins, appropriate action limits should be established and
      met.

11.14 Laboratory controls should be followed and documented at the time of
      performance. Any departures from the above described procedures should be
      documented and explained.

11.15 Any out-of-specification result obtained should be investigated and documented
      according to a procedure. This procedure should require analysis of the data,
      assessment of whether a significant problem exists, allocation of the tasks for
      corrective actions, and conclusions. Any resampling and/or retesting after OOS
      results should be performed according to a documented procedure.

11.16 Reagents and standard solutions should be prepared and labelled following
      written procedures. “Use by” dates should be applied as appropriate for
      analytical reagents or standard solutions.

11.17 Primary reference standards should be obtained as appropriate for the
      manufacture of APIs. The source of each primary reference standard should be
      documented. Records should be maintained of each primary reference
      standard’s storage and use in accordance with the supplier’s recommendations.
      Primary reference standards obtained from an officially recognised source are
      normally used without testing if stored under conditions consistent with the
      supplier’s recommendations.

11.18 Where a primary reference standard is not available from an officially recognized
      source, an “in-house primary standard” should be established. Appropriate



 PE 009-17 (Part II)                       - 26 -                         25 August 2023
                                                                      Laboratory Controls



       testing should be performed to establish fully the identity and purity of the primary
       reference standard. Appropriate documentation of this testing should be
       maintained.

11.19 Secondary reference standards should be appropriately prepared, identified,
      tested, approved, and stored. The suitability of each batch of secondary
      reference standard should be determined prior to first use by comparing against
      a primary reference standard. Each batch of secondary reference standard
      should be periodically requalified in accordance with a written protocol.

11.2   Testing of Intermediates and APIs

11.20 For each batch of intermediate and API, appropriate laboratory tests should be
      conducted to determine conformance to specifications.

11.21 An impurity profile describing the identified and unidentified impurities present in
      a typical batch produced by a specific controlled production process should
      normally be established for each API. The impurity profile should include the
      identity or some qualitative analytical designation (e.g. retention time), the range
      of each impurity observed, and classification of each identified impurity (e.g.
      inorganic, organic, solvent). The impurity profile is normally dependent upon the
      production process and origin of the API. Impurity profiles are normally not
      necessary for APIs from herbal or animal tissue origin. Biotechnology
      considerations are covered in ICH Guideline Q6B.

11.22 The impurity profile should be compared at appropriate intervals against the
      impurity profile in the regulatory submission or compared against historical data
      in order to detect changes to the API resulting from modifications in raw materials,
      equipment operating parameters, or the production process.

11.23 Appropriate microbiological tests should be conducted on each batch of
      intermediate and API where microbial quality is specified.

11.3   Validation of Analytical Procedures - see Section 12.

11.4   Certificates of Analysis

11.40 Authentic Certificates of Analysis should be issued for each batch of intermediate
      or API on request.

11.41 Information on the name of the intermediate or API including where appropriate
      its grade, the batch number, and the date of release should be provided on the
      Certificate of Analysis. For intermediates or APIs with an expiry date, the expiry
      date should be provided on the label and Certificate of Analysis. For
      intermediates or APIs with a retest date, the retest date should be indicated on
      the label and/or Certificate of Analysis.

11.42 The Certificate should list each test performed in accordance with compendial or
      customer requirements, including the acceptance limits, and the numerical
      results obtained (if test results are numerical).

11.43 Certificates should be dated and signed by authorised personnel of the quality
      unit(s) and should show the name, address and telephone number of the original
      manufacturer. Where the analysis has been carried out by a repacker or


 PE 009-17 (Part II)                       - 27 -                          25 August 2023
                                                                       Laboratory Controls



       reprocessor, the Certificate of Analysis should show the name, address and
       telephone number of the repacker/reprocessor and a reference to the name of
       the original manufacturer.

11.44 If new Certificates are issued by or on behalf of repackers/reprocessors, agents
      or brokers, these Certificates should show the name, address and telephone
      number of the laboratory that performed the analysis. They should also contain a
      reference to the name and address of the original manufacturer and to the original
      batch Certificate, a copy of which should be attached.

11.5   Stability Monitoring of APIs

11.50 A documented, on-going testing program should be designed to monitor the
      stability characteristics of APIs, and the results should be used to confirm
      appropriate storage conditions and retest or expiry dates.

11.51 The test procedures used in stability testing should be validated and be stability
      indicating.

11.52 Stability samples should be stored in containers that simulate the market
      container. For example, if the API is marketed in bags within fiber drums, stability
      samples can be packaged in bags of the same material and in smaller-scale
      drums of similar or identical material composition to the market drums.

11.53 Normally the first three commercial production batches should be placed on the
      stability monitoring program to confirm the retest or expiry date. However, where
      data from previous studies show that the API is expected to remain stable for at
      least two years, fewer than three batches can be used.

11.54 Thereafter, at least one batch per year of API manufactured (unless none is
      produced that year) should be added to the stability monitoring program and
      tested at least annually to confirm the stability.

11.55 For APIs with short shelf-lives, testing should be done more frequently. For
      example, for those biotechnological/biologic and other APIs with shelf-lives of one
      year or less, stability samples should be obtained and should be tested monthly
      for the first three months, and at three month intervals after that. When data exist
      that confirm that the stability of the API is not compromised, elimination of specific
      test intervals (e.g. 9 month testing) can be considered.

11.56 Where appropriate, the stability storage conditions should be consistent with the
      ICH guidelines on stability.

11.6   Expiry and Retest Dating

11.60 When an intermediate is intended to be transferred outside the control of the
      manufacturer’s material management system and an expiry or retest date is
      assigned, supporting stability information should be available (e.g. published
      data, test results).

11.61 An API expiry or retest date should be based on an evaluation of data derived
      from stability studies. Common practice is to use a retest date, not an expiration
      date.



 PE 009-17 (Part II)                       - 28 -                          25 August 2023
                                                                                   Validation




11.62 Preliminary API expiry or retest dates can be based on pilot scale batches if (1)
      the pilot batches employ a method of manufacture and procedure that simulates
      the final process to be used on a commercial manufacturing scale; and (2) the
      quality of the API represents the material to be made on a commercial scale.

11.63 A representative sample should be taken for the purpose of performing a retest.

11.7   Reserve/Retention Samples

11.70 The packaging and holding of reserve samples is for the purpose of potential
      future evaluation of the quality of batches of API and not for future stability testing
      purposes.

11.71 Appropriately identified reserve samples of each API batch should be retained for
      one year after the expiry date of the batch assigned by the manufacturer, or for
      three years after distribution of the batch, whichever is the longer. For APIs with
      retest dates, similar reserve samples should be retained for three years after the
      batch is completely distributed by the manufacturer.

11.72 The reserve sample should be stored in the same packaging system in which the
      API is stored or in one that is equivalent to or more protective than the marketed
      packaging system. Sufficient quantities should be retained to conduct at least
      two full compendial analyses or, when there is no pharmacopoeial monograph,
      two full specification analyses.


12.    VALIDATION

12.1   Validation Policy

12.10 The company's overall policy, intentions, and approach to validation, including
      the validation of production processes, cleaning procedures, analytical methods,
      in-process control test procedures, computerized systems, and persons
      responsible for design, review, approval and documentation of each validation
      phase, should be documented.

12.11 The critical parameters/attributes should normally be identified during the
      development stage or from historical data, and the ranges necessary for the
      reproducible operation should be defined. This should include:
             Defining the API in terms of its critical product attributes;
             Identifying process parameters that could affect the critical quality attributes
              of the API;
             Determining the range for each critical process parameter expected to be
              used during routine manufacturing and process control.

12.12 Validation should extend to those operations determined to be critical to the
      quality and purity of the API.




 PE 009-17 (Part II)                        - 29 -                            25 August 2023
                                                                               Validation



12.2   Validation Documentation

12.20 A written validation protocol should be established that specifies how validation
      of a particular process will be conducted. The protocol should be reviewed and
      approved by the quality unit(s) and other designated units.

12.21 The validation protocol should specify critical process steps and acceptance
      criteria as well as the type of validation to be conducted (e.g. retrospective,
      prospective, concurrent) and the number of process runs.

12.22 A validation report that cross-references the validation protocol should be
      prepared, summarising the results obtained, commenting on any deviations
      observed, and drawing the appropriate conclusions, including recommending
      changes to correct deficiencies.

12.23 Any variations from the validation protocol should be documented with
      appropriate justification.

12.3   Qualification

12.30 Before starting process validation activities, appropriate qualification of critical
      equipment and ancillary systems should be completed. Qualification is usually
      carried out by conducting the following activities, individually or combined:
             Design Qualification (DQ): documented verification that the proposed
              design of the facilities, equipment, or systems is suitable for the intended
              purpose.
             Installation Qualification (IQ): documented verification that the equipment
              or systems, as installed or modified, comply with the approved design, the
              manufacturer’s recommendations and/or user requirements.
             Operational Qualification (OQ): documented verification that the equipment
              or systems, as installed or modified, perform as intended throughout the
              anticipated operating ranges.
             Performance Qualification (PQ): documented verification that the
              equipment and ancillary systems, as connected together, can perform
              effectively and reproducibly based on the approved process method and
              specifications.

12.4   Approaches to Process Validation

12.40 Process Validation (PV) is the documented evidence that the process, operated
      within established parameters, can perform effectively and reproducibly to
      produce an intermediate or API meeting its predetermined specifications and
      quality attributes.

12.41 There are three approaches to validation. Prospective validation is the preferred
      approach, but there are exceptions where the other approaches can be used.
      These approaches and their applicability are listed below.

12.42 Prospective validation should normally be performed for all API processes as
      defined in 12.12. Prospective validation performed on an API process should be



 PE 009-17 (Part II)                      - 30 -                          25 August 2023
                                                                               Validation



       completed before the commercial distribution of the final drug product
       manufactured from that API.

12.43 Concurrent validation can be conducted when data from replicate production runs
      are unavailable because only a limited number of API batches have been
      produced, API batches are produced infrequently, or API batches are produced
      by a validated process that has been modified. Prior to the completion of
      concurrent validation, batches can be released and used in final drug product for
      commercial distribution based on thorough monitoring and testing of the API
      batches.

12.44 An exception can be made for retrospective validation for well established
      processes that have been used without significant changes to API quality due to
      changes in raw materials, equipment, systems, facilities, or the production
      process. This validation approach may be used where:

       (1)    Critical quality attributes and critical process parameters have been
              identified;

       (2)    Appropriate in-process acceptance criteria and controls have been
              established;

       (3)    There have not been significant process/product failures attributable to
              causes other than operator error or equipment failures unrelated to
              equipment suitability; and

       (4)    Impurity profiles have been established for the existing API.

12.45 Batches selected for retrospective validation should be representative of all
      batches made during the review period, including any batches that failed to meet
      specifications, and should be sufficient in number to demonstrate process
      consistency. Retained samples can be tested to obtain data to retrospectively
      validate the process.

12.5   Process Validation Program

12.50 The number of process runs for validation should depend on the complexity of
      the process or the magnitude of the process change being considered. For
      prospective and concurrent validation, three consecutive successful production
      batches should be used as a guide, but there may be situations where additional
      process runs are warranted to prove consistency of the process (e.g., complex
      API processes or API processes with prolonged completion times). For
      retrospective validation, generally data from ten to thirty consecutive batches
      should be examined to assess process consistency, but fewer batches can be
      examined if justified.

12.51 Critical process parameters should be controlled and monitored during process
      validation studies. Process parameters unrelated to quality, such as variables
      controlled to minimize energy consumption or equipment use, need not be
      included in the process validation.

12.52 Process validation should confirm that the impurity profile for each API is within
      the limits specified. The impurity profile should be comparable to or better than


 PE 009-17 (Part II)                      - 31 -                          25 August 2023
                                                                               Validation



       historical data and, where applicable, the profile determined during process
       development or for batches used for pivotal clinical and toxicological studies.

12.6   Periodic Review of Validated Systems

12.60 Systems and processes should be periodically evaluated to verify that they are
      still operating in a valid manner. Where no significant changes have been made
      to the system or process, and a quality review confirms that the system or process
      is consistently producing material meeting its specifications, there is normally no
      need for revalidation.

12.7   Cleaning Validation

12.70 Cleaning procedures should normally be validated. In general, cleaning
      validation should be directed to situations or process steps where contamination
      or carryover of materials poses the greatest risk to API quality. For example, in
      early production it may be unnecessary to validate equipment cleaning
      procedures where residues are removed by subsequent purification steps.

12.71 Validation of cleaning procedures should reflect actual equipment usage
      patterns. If various APIs or intermediates are manufactured in the same
      equipment and the equipment is cleaned by the same process, a representative
      intermediate or API can be selected for cleaning validation. This selection should
      be based on the solubility and difficulty of cleaning and the calculation of residue
      limits based on potency, toxicity, and stability.

12.72 The cleaning validation protocol should describe the equipment to be cleaned,
      procedures, materials, acceptable cleaning levels, parameters to be monitored
      and controlled, and analytical methods. The protocol should also indicate the
      type of samples to be obtained and how they are collected and labelled.

12.73 Sampling should include swabbing, rinsing, or alternative methods (e.g., direct
      extraction), as appropriate, to detect both insoluble and soluble residues. The
      sampling methods used should be capable of quantitatively measuring levels of
      residues remaining on the equipment surfaces after cleaning. Swab sampling
      may be impractical when product contact surfaces are not easily accessible due
      to equipment design and/or process limitations (e.g., inner surfaces of hoses,
      transfer pipes, reactor tanks with small ports or handling toxic materials, and
      small intricate equipment such as micronizers and microfluidizers).

12.74 Validated analytical methods having sensitivity to detect residues or
      contaminants should be used. The detection limit for each analytical method
      should be sufficiently sensitive to detect the established acceptable level of the
      residue or contaminant. The method’s attainable recovery level should be
      established. Residue limits should be practical, achievable, verifiable and based
      on the most deleterious residue. Limits can be established based on the
      minimum known pharmacological, toxicological, or physiological activity of the
      API or its most deleterious component.

12.75 Equipment cleaning/sanitization studies should address microbiological and
      endotoxin contamination for those processes where there is a need to reduce
      total microbiological count or endotoxins in the API, or other processes where




 PE 009-17 (Part II)                      - 32 -                          25 August 2023
                                                                        Change Control



       such contamination could be of concern (e.g., non-sterile APIs used to
       manufacture sterile products).

12.76 Cleaning procedures should be monitored at appropriate intervals after validation
      to ensure that these procedures are effective when used during routine
      production. Equipment cleanliness can be monitored by analytical testing and
      visual examination, where feasible. Visual inspection can allow detection of
      gross contamination concentrated in small areas that could otherwise go
      undetected by sampling and/or analysis.

12.8   Validation of Analytical Methods

12.80 Analytical methods should be validated unless the method employed is included
      in the relevant pharmacopoeia or other recognised standard reference. The
      suitability of all testing methods used should nonetheless be verified under actual
      conditions of use and documented.

12.81 Methods should be validated to include consideration of characteristics included
      within the ICH guidelines on validation of analytical methods. The degree of
      analytical validation performed should reflect the purpose of the analysis and the
      stage of the API production process.

12.82 Appropriate qualification of analytical equipment should be considered before
      starting validation of analytical methods.

12.83 Complete records should be maintained of any modification of a validated
      analytical method. Such records should include the reason for the modification
      and appropriate data to verify that the modification produces results that are as
      accurate and reliable as the established method.


13.    CHANGE CONTROL

13.10 A formal change control system should be established to evaluate all changes
      that may affect the production and control of the intermediate or API.

13.11 Written procedures should provide for the identification, documentation,
      appropriate review, and approval of changes in raw materials, specifications,
      analytical methods, facilities, support systems, equipment (including computer
      hardware), processing steps, labelling and packaging materials, and computer
      software.

13.12 Any proposals for GMP relevant changes should be drafted, reviewed, and
      approved by the appropriate organisational units, and reviewed and approved by
      the quality unit(s).

13.13 The potential impact of the proposed change on the quality of the intermediate or
      API should be evaluated. A classification procedure may help in determining the
      level of testing, validation, and documentation needed to justify changes to a
      validated process. Changes can be classified (e.g. as minor or major) depending
      on the nature and extent of the changes, and the effects these changes may
      impart on the process. Scientific judgement should determine what additional



 PE 009-17 (Part II)                      - 33 -                         25 August 2023
                                                     Rejection and Re-Use of Materials



       testing and validation studies are appropriate to justify a change in a validated
       process.

13.14 When implementing approved changes, measures should be taken to ensure that
      all documents affected by the changes are revised.

13.15 After the change has been implemented, there should be an evaluation of the
      first batches produced or tested under the change.

13.16 The potential for critical changes to affect established retest or expiry dates
      should be evaluated. If necessary, samples of the intermediate or API produced
      by the modified process can be placed on an accelerated stability program and/or
      can be added to the stability monitoring program.

13.17 Current dosage form manufacturers should be notified of changes from
      established production and process control procedures that can impact the
      quality of the API.


14.    REJECTION AND RE-USE OF MATERIALS

14.1   Rejection

14.10 Intermediates and APIs failing to meet established specifications should be
      identified as such and quarantined. These intermediates or APIs can be
      reprocessed or reworked as described below. The final disposition of rejected
      materials should be recorded.

14.2   Reprocessing

14.20 Introducing an intermediate or API, including one that does not conform to
      standards or specifications, back into the process and reprocessing by repeating
      a crystallization step or other appropriate chemical or physical manipulation steps
      (e.g., distillation, filtration, chromatography, milling) that are part of the
      established manufacturing process is generally considered acceptable.
      However, if such reprocessing is used for a majority of batches, such
      reprocessing should be included as part of the standard manufacturing process.

14.21 Continuation of a process step after an in-process control test has shown that the
      step is incomplete is considered to be part of the normal process. This is not
      considered to be reprocessing.

14.22 Introducing unreacted material back into a process and repeating a chemical
      reaction is considered to be reprocessing unless it is part of the established
      process. Such reprocessing should be preceded by careful evaluation to ensure
      that the quality of the intermediate or API is not adversely impacted due to the
      potential formation of by-products and over-reacted materials.




 PE 009-17 (Part II)                      - 34 -                         25 August 2023
                                                     Rejection and Re-Use of Materials



14.3   Reworking

14.30 Before a decision is taken to rework batches that do not conform to established
      standards or specifications, an investigation into the reason for non-conformance
      should be performed.

14.31 Batches that have been reworked should be subjected to appropriate evaluation,
      testing, stability testing if warranted, and documentation to show that the
      reworked product is of equivalent quality to that produced by the original process.
      Concurrent validation is often the appropriate validation approach for rework
      procedures. This allows a protocol to define the rework procedure, how it will be
      carried out, and the expected results. If there is only one batch to be reworked,
      then a report can be written and the batch released once it is found to be
      acceptable.

14.32 Procedures should provide for comparing the impurity profile of each reworked
      batch against batches manufactured by the established process. Where routine
      analytical methods are inadequate to characterize the reworked batch, additional
      methods should be used.

14.4   Recovery of Materials and Solvents

14.40 Recovery (e.g. from mother liquor or filtrates) of reactants, intermediates, or the
      API is considered acceptable, provided that approved procedures exist for the
      recovery and the recovered materials meet specifications suitable for their
      intended use.

14.41 Solvents can be recovered and reused in the same processes or in different
      processes, provided that the recovery procedures are controlled and monitored
      to ensure that solvents meet appropriate standards before reuse or co-mingling
      with other approved materials.

14.42 Fresh and recovered solvents and reagents can be combined if adequate testing
      has shown their suitability for all manufacturing processes in which they may be
      used.

14.43 The use of recovered solvents, mother liquors, and other recovered materials
      should be adequately documented.

14.5   Returns

14.50 Returned intermediates or APIs should be identified as such and quarantined.

14.51 If the conditions under which returned intermediates or APIs have been stored or
      shipped before or during their return or the condition of their containers casts
      doubt on their quality, the returned intermediates or APIs should be reprocessed,
      reworked, or destroyed, as appropriate.

14.52 Records of returned intermediates or APIs should be maintained. For each return,
      documentation should include:
             Name and address of the consignee
             Intermediate or API, batch number, and quantity returned


 PE 009-17 (Part II)                      - 35 -                         25 August 2023
                                                                Complaints and Recalls
                                         Contract Manufacturers (Including Laboratories)


             Reason for return
             Use or disposal of the returned intermediate or API


15.    COMPLAINTS AND RECALLS

15.10 All quality related complaints, whether received orally or in writing, should be
      recorded and investigated according to a written procedure.

15.11 Complaint records should include:
             Name and address of complainant;
             Name (and, where appropriate, title) and phone number of person
              submitting the complaint;
             Complaint nature (including name and batch number of the API);
             Date complaint is received;
             Action initially taken (including dates and identity of person taking the
              action);
             Any follow-up action taken;
             Response provided to the originator of complaint (including date response
              sent); and
             Final decision on intermediate or API batch or lot.

15.12 Records of complaints should be retained in order to evaluate trends, product-
      related frequencies, and severity with a view to taking additional, and if
      appropriate, immediate corrective action.

15.13 There should be a written procedure that defines the circumstances under which
      a recall of an intermediate or API should be considered.

15.14 The recall procedure should designate who should be involved in evaluating the
      information, how a recall should be initiated, who should be informed about the
      recall, and how the recalled material should be treated.

15.15 In the event of a serious or potentially life-threatening situation, local, national,
      and/or international authorities should be informed and their advice sought.


16.    CONTRACT MANUFACTURERS (INCLUDING LABORATORIES)

16.10 All contract manufacturers (including laboratories) should comply with the GMP
      defined in this Guide. Special consideration should be given to the prevention of
      cross-contamination and to maintaining traceability.

16.11 Contract manufacturers (including laboratories) should be evaluated by the
      contract giver to ensure GMP compliance of the specific operations occurring at
      the contract sites.




 PE 009-17 (Part II)                        - 36 -                        25 August 2023
                       Agents, Brokers, Traders, Distributors, Repackers and Relabellers



16.12 There should be a written and approved contract or formal agreement between
      the contract giver and the contract acceptor that defines in detail the GMP
      responsibilities, including the quality measures, of each party.

16.13 The contract should permit the contract giver to audit the contract acceptor's
      facilities for compliance with GMP.

16.14 Where subcontracting is allowed, the contract acceptor should not pass to a third
      party any of the work entrusted to him under the contract without the contract
      giver's prior evaluation and approval of the arrangements.

16.15 Manufacturing and laboratory records should be kept at the site where the activity
      occurs and be readily available.

16.16 Changes in the process, equipment, test methods, specifications, or other
      contractual requirements should not be made unless the contract giver is
      informed and approves the changes.


17.    AGENTS, BROKERS, TRADERS, DISTRIBUTORS, REPACKERS AND
       RELABELLERS

17.1   Applicability

17.10 This section applies to any party other than the original manufacturer who may
      trade and/or take possession, repack, relabel, manipulate, distribute or store an
      API or intermediate.

17.11 All agents, brokers, traders, distributors, repackers, and relabellers should
      comply with GMP as defined in this Guide.

17.2   Traceability of Distributed APIs and Intermediates

17.20 Agents, brokers, traders, distributors, repackers, or relabellers should maintain
      complete traceability of APIs and intermediates that they distribute. Documents
      that should be retained and available include:
             Identity of original manufacturer
             Address of original manufacturer
             Purchase orders
             Bills of lading (transportation documentation)
             Receipt documents
             Name or designation of API or intermediate
             Manufacturer’s batch number
             Transportation and distribution records
             All authentic Certificates of Analysis, including those of the original
              manufacturer
             Retest or expiry date




 PE 009-17 (Part II)                       - 37 -                       25 August 2023
                       Agents, Brokers, Traders, Distributors, Repackers and Relabellers



17.3   Quality Management

17.30 Agents, brokers, traders, distributors, repackers, or relabellers should establish,
      document and implement an effective system of managing quality, as specified
      in Section 2.

17.4   Repackaging, Relabelling and Holding of APIs and Intermediates

17.40 Repackaging, relabelling and holding of APIs and intermediates should be
      performed under appropriate GMP controls, as stipulated in this Guide, to avoid
      mix-ups and loss of API or intermediate identity or purity.

17.41 Repackaging should be conducted under appropriate environmental conditions
      to avoid contamination and cross-contamination.

17.5   Stability

17.50 Stability studies to justify assigned expiration or retest dates should be conducted
      if the API or intermediate is repackaged in a different type of container than that
      used by the API or intermediate manufacturer.

17.6   Transfer of Information

17.60 Agents, brokers, distributors, repackers, or relabellers should transfer all quality
      or regulatory information received from an API or intermediate manufacturer to
      the customer, and from the customer to the API or intermediate manufacturer.

17.61 The agent, broker, trader, distributor, repacker, or relabeller who supplies the API
      or intermediate to the customer should provide the name of the original API or
      intermediate manufacturer and the batch number(s) supplied.

17.62 The agent should also provide the identity of the original API or intermediate
      manufacturer to regulatory authorities upon request. The original manufacturer
      can respond to the regulatory authority directly or through its authorized agents,
      depending on the legal relationship between the authorized agents and the
      original API or intermediate manufacturer. (In this context "authorized" refers to
      authorized by the manufacturer.)

17.63 The specific guidance for Certificates of Analysis included in Section 11.4 should
      be met.

17.7   Handling of Complaints and Recalls

17.70 Agents, brokers, traders, distributors, repackers, or relabellers should maintain
      records of complaints and recalls, as specified in Section 15, for all complaints
      and recalls that come to their attention.

17.71 If the situation warrants, the agents, brokers, traders, distributors, repackers, or
      relabellers should review the complaint with the original API or intermediate
      manufacturer in order to determine whether any further action, either with other
      customers who may have received this API or intermediate or with the regulatory
      authority, or both, should be initiated. The investigation into the cause for the



 PE 009-17 (Part II)                      - 38 -                          25 August 2023
                  Specific Guidance for APIs Manufactured by Cell Culture/Fermentation



       complaint or recall should be conducted and documented by the appropriate
       party.

17.72 Where a complaint is referred to the original API or intermediate manufacturer,
      the record maintained by the agents, brokers, traders, distributors, repackers, or
      relabellers should include any response received from the original API or
      intermediate manufacturer (including date and information provided).

17.8   Handling of Returns

17.80 Returns should be handled as specified in Section 14.52. The agents, brokers,
      traders, distributors, repackers, or relabellers should maintain documentation of
      returned APIs and intermediates.


18.    SPECIFIC GUIDANCE FOR APIs MANUFACTURED BY CELL
       CULTURE/FERMENTATION

18.1   General

18.10 Section 18 is intended to address specific controls for APIs or intermediates
      manufactured by cell culture or fermentation using natural or recombinant
      organisms and that have not been covered adequately in the previous sections.
      It is not intended to be a stand-alone Section. In general, the GMP principles in
      the other sections of this document apply. Note that the principles of fermentation
      for “classical” processes for production of small molecules and for processes
      using recombinant and non-recombinant organisms for production of proteins
      and/or polypeptides are the same, although the degree of control will differ.
      Where practical, this section will address these differences. In general, the
      degree of control for biotechnological processes used to produce proteins and
      polypeptides is greater than that for classical fermentation processes.

18.11 The term “biotechnological process” (biotech) refers to the use of cells or
      organisms that have been generated or modified by recombinant DNA,
      hybridoma or other technology to produce APIs. The APIs produced by
      biotechnological processes normally consist of high molecular weight
      substances, such as proteins and polypeptides, for which specific guidance is
      given in this Section. Certain APIs of low molecular weight, such as antibiotics,
      amino acids, vitamins, and carbohydrates, can also be produced by recombinant
      DNA technology. The level of control for these types of APIs is similar to that
      employed for classical fermentation.

18.12 The term “classical fermentation” refers to processes that use microorganisms
      existing in nature and/or modified by conventional methods (e.g. irradiation or
      chemical mutagenesis) to produce APIs.          APIs produced by “classical
      fermentation” are normally low molecular weight products such as antibiotics,
      amino acids, vitamins, and carbohydrates.

18.13 Production of APIs or intermediates from cell culture or fermentation involves
      biological processes such as cultivation of cells or extraction and purification of
      material from living organisms. Note that there may be additional process steps,
      such as physicochemical modification, that are part of the manufacturing process.
      The raw materials used (media, buffer components) may provide the potential for


 PE 009-17 (Part II)                      - 39 -                         25 August 2023
                  Specific Guidance for APIs Manufactured by Cell Culture/Fermentation



       growth of microbiological contaminants. Depending on the source, method of
       preparation, and the intended use of the API or intermediate, control of
       bioburden, viral contamination, and/or endotoxins during manufacturing and
       monitoring of the process at appropriate stages may be necessary.

18.14 Appropriate controls should be established at all stages of manufacturing to
      assure intermediate and/or API quality. While this Guide starts at the cell
      culture/fermentation step, prior steps (e.g. cell banking) should be performed
      under appropriate process controls. This Guide covers cell culture/fermentation
      from the point at which a vial of the cell bank is retrieved for use in manufacturing.

18.15 Appropriate equipment and environmental controls should be used to minimize
      the risk of contamination. The acceptance criteria for quality of the environment
      and the frequency of monitoring should depend on the step in production and the
      production conditions (open, closed, or contained systems).

18.16 In general, process controls should take into account:
             Maintenance of the Working Cell Bank (where appropriate);
             Proper inoculation and expansion of the culture;
             Control of the critical operating parameters during fermentation/cell culture;
             Monitoring of the process for cell growth, viability (for most cell culture
              processes) and productivity where appropriate;
             Harvest and purification procedures that remove cells, cellular debris and
              media components while protecting the intermediate or API from
              contamination (particularly of a microbiological nature) and from loss of
              quality;
             Monitoring of bioburden and, where needed, endotoxin levels at
              appropriate stages of production; and
             Viral safety concerns as described in ICH Guideline Q5A Quality of
              Biotechnological Products: Viral Safety Evaluation of Biotechnology
              Products Derived from Cell Lines of Human or Animal Origin.

18.17 Where appropriate, the removal of media components, host cell proteins, other
      process-related impurities, product-related impurities and contaminants should
      be demonstrated.

18.2   Cell Bank Maintenance and Record Keeping

18.20 Access to cell banks should be limited to authorized personnel.

18.21 Cell banks should be maintained under storage conditions designed to maintain
      viability and prevent contamination.

18.22 Records of the use of the vials from the cell banks and storage conditions should
      be maintained.

18.23 Where appropriate, cell banks should be periodically monitored to determine
      suitability for use.

18.24 See ICH Guideline Q5D Quality of Biotechnological Products: Derivation and
      Characterization  of  Cell    Substrates    Used     for   Production   of


 PE 009-17 (Part II)                       - 40 -                          25 August 2023
                  Specific Guidance for APIs Manufactured by Cell Culture/Fermentation



       Biotechnological/Biological Products for a more complete discussion of cell
       banking.

18.3   Cell Culture/Fermentation

18.30 Where aseptic addition of cell substrates, media, buffers, and gases is needed,
      closed or contained systems should be used where possible. If the inoculation
      of the initial vessel or subsequent transfers or additions (media, buffers) are
      performed in open vessels, there should be controls and procedures in place to
      minimize the risk of contamination.

18.31 Where the quality of the API can be affected by microbial contamination,
      manipulations using open vessels should be performed in a biosafety cabinet or
      similarly controlled environment.

18.32 Personnel should be appropriately gowned and take special precautions handling
      the cultures.

18.33 Critical operating parameters (for example temperature, pH, agitation rates,
      addition of gases, pressure) should be monitored to ensure consistency with the
      established process. Cell growth, viability (for most cell culture processes), and,
      where appropriate, productivity should also be monitored. Critical parameters
      will vary from one process to another, and for classical fermentation, certain
      parameters (cell viability, for example) may not need to be monitored.

18.34 Cell culture equipment should be cleaned and sterilized after use. As
      appropriate, fermentation equipment should be cleaned, and sanitized or
      sterilized.

18.35 Culture media should be sterilized before use when appropriate to protect the
      quality of the API.

18.36 There should be appropriate procedures in place to detect contamination and
      determine the course of action to be taken. This should include procedures to
      determine the impact of the contamination on the product and those to
      decontaminate the equipment and return it to a condition to be used in
      subsequent batches.      Foreign organisms observed during fermentation
      processes should be identified as appropriate and the effect of their presence on
      product quality should be assessed, if necessary. The results of such
      assessments should be taken into consideration in the disposition of the material
      produced.

18.37 Records of contamination events should be maintained.

18.38 Shared (multi-product) equipment may warrant additional testing after cleaning
      between product campaigns, as appropriate, to minimize the risk of cross-
      contamination.




 PE 009-17 (Part II)                      - 41 -                         25 August 2023
                                                           APIs for Use in Clinical Trials



18.4   Harvesting, Isolation and Purification

18.40 Harvesting steps, either to remove cells or cellular components or to collect
      cellular components after disruption, should be performed in equipment and
      areas designed to minimize the risk of contamination.

18.41 Harvest and purification procedures that remove or inactivate the producing
      organism, cellular debris and media components (while minimizing degradation,
      contamination, and loss of quality) should be adequate to ensure that the
      intermediate or API is recovered with consistent quality.

18.42 All equipment should be properly cleaned and, as appropriate, sanitized after
      use. Multiple successive batching without cleaning can be used if intermediate
      or API quality is not compromised.

18.43 If open systems are used, purification should be performed under environmental
      conditions appropriate for the preservation of product quality.

18.44 Additional controls, such as the use of dedicated chromatography resins or
      additional testing, may be appropriate if equipment is to be used for multiple
      products.

18.5   Viral Removal/Inactivation Steps

18.50 See the ICH Guideline Q5A Quality of Biotechnological Products: Viral Safety
      Evaluation of Biotechnology Products Derived from Cell Lines of Human or
      Animal Origin for more specific information.

18.51 Viral removal and viral inactivation steps are critical processing steps for some
      processes and should be performed within their validated parameters.

18.52 Appropriate precautions should be taken to prevent potential viral contamination
      from pre-viral to post-viral removal/inactivation steps.       Therefore, open
      processing should be performed in areas that are separate from other processing
      activities and have separate air handling units.

18.53 The same equipment is not normally used for different purification steps.
      However, if the same equipment is to be used, the equipment should be
      appropriately cleaned and sanitized before reuse. Appropriate precautions
      should be taken to prevent potential virus carry-over (e.g. through equipment or
      environment) from previous steps.


19.    APIs FOR USE IN CLINICAL TRIALS

19.1   General

19.10 Not all the controls in the previous sections of this Guide are appropriate for the
      manufacture of a new API for investigational use during its development. Section
      19 provides specific guidance unique to these circumstances.

19.11 The controls used in the manufacture of APIs for use in clinical trials should be
      consistent with the stage of development of the drug product incorporating the
      API. Process and test procedures should be flexible to provide for changes as



 PE 009-17 (Part II)                      - 42 -                         25 August 2023
                                                            APIs for Use in Clinical Trials



       knowledge of the process increases and clinical testing of a drug product
       progresses from pre-clinical stages through clinical stages. Once drug
       development reaches the stage where the API is produced for use in drug
       products intended for clinical trials, manufacturers should ensure that APIs are
       manufactured in suitable facilities using appropriate production and control
       procedures to ensure the quality of the API.

19.2   Quality

19.20 Appropriate GMP concepts should be applied in the production of APIs for use in
      clinical trials with a suitable mechanism of approval of each batch.

19.21 A quality unit(s) independent from production should be established for the
      approval or rejection of each batch of API for use in clinical trials.

19.22 Some of the testing functions commonly performed by the quality unit(s) can be
      performed within other organizational units.

19.23 Quality measures should include a system for testing of raw materials, packaging
      materials, intermediates, and APIs.

19.24 Process and quality problems should be evaluated.

19.25 Labelling for APIs intended for use in clinical trials should be appropriately
      controlled and should identify the material as being for investigational use.

19.3   Equipment and Facilities

19.30 During all phases of clinical development, including the use of small-scale
      facilities or laboratories to manufacture batches of APIs for use in clinical trials,
      procedures should be in place to ensure that equipment is calibrated, clean and
      suitable for its intended use.

19.31 Procedures for the use of facilities should ensure that materials are handled in a
      manner that minimizes the risk of contamination and cross-contamination.

19.4   Control of Raw Materials

19.40 Raw materials used in production of APIs for use in clinical trials should be
      evaluated by testing, or received with a supplier’s analysis and subjected to
      identity testing. When a material is considered hazardous, a supplier's analysis
      should suffice.

19.41 In some instances, the suitability of a raw material can be determined before use
      based on acceptability in small-scale reactions (i.e., use testing) rather than on
      analytical testing alone.

19.5   Production

19.50 The production of APIs for use in clinical trials should be documented in
      laboratory notebooks, batch records, or by other appropriate means. These
      documents should include information on the use of production materials,
      equipment, processing, and scientific observations.




 PE 009-17 (Part II)                       - 43 -                         25 August 2023
                                                           APIs for Use in Clinical Trials



19.51 Expected yields can be more variable and less defined than the expected yields
      used in commercial processes. Investigations into yield variations are not
      expected.

19.6   Validation

19.60 Process validation for the production of APIs for use in clinical trials is normally
      inappropriate, where a single API batch is produced or where process changes
      during API development make batch replication difficult or inexact. The
      combination of controls, calibration, and, where appropriate, equipment
      qualification assures API quality during this development phase.

19.61 Process validation should be conducted in accordance with Section 12 when
      batches are produced for commercial use, even when such batches are produced
      on a pilot or small scale.

19.7   Changes

19.70 Changes are expected during development, as knowledge is gained and the
      production is scaled up. Every change in the production, specifications, or test
      procedures should be adequately recorded.

19.8   Laboratory Controls

19.80 While analytical methods performed to evaluate a batch of API for clinical trials
      may not yet be validated, they should be scientifically sound.

19.81 A system for retaining reserve samples of all batches should be in place. This
      system should ensure that a sufficient quantity of each reserve sample is retained
      for an appropriate length of time after approval, termination, or discontinuation of
      an application.

19.82 Expiry and retest dating as defined in Section 11.6 applies to existing APIs used
      in clinical trials. For new APIs, Section 11.6 does not normally apply in early
      stages of clinical trials.

19.9   Documentation

19.90 A system should be in place to ensure that information gained during the
      development and the manufacture of APIs for use in clinical trials is documented
      and available.

19.91 The development and implementation of the analytical methods used to support
      the release of a batch of API for use in clinical trials should be appropriately
      documented.

19.92 A system for retaining production and control records and documents should be
      used. This system should ensure that records and documents are retained for an
      appropriate length of time after the approval, termination, or discontinuation of an
      application.




 PE 009-17 (Part II)                      - 44 -                          25 August 2023
                                                                                Glossary



20.    GLOSSARY

       Acceptance Criteria

       Numerical limits, ranges, or other suitable measures for acceptance of test
       results.

       Active Pharmaceutical Ingredient (API) (or Drug Substance)

       Any substance or mixture of substances intended to be used in the manufacture
       of a drug (medicinal) product and that, when used in the production of a drug,
       becomes an active ingredient of the drug product. Such substances are intended
       to furnish pharmacological activity or other direct effect in the diagnosis, cure,
       mitigation, treatment, or prevention of disease or to affect the structure and
       function of the body.

       API Starting Material

       A raw material, intermediate, or an API that is used in the production of an API
       and that is incorporated as a significant structural fragment into the structure of
       the API. An API Starting Material can be an article of commerce, a material
       purchased from one or more suppliers under contract or commercial agreement,
       or produced in-house. API Starting Materials are normally of defined chemical
       properties and structure.

       Batch (or Lot)

       A specific quantity of material produced in a process or series of processes so
       that it is expected to be homogeneous within specified limits. In the case of
       continuous production, a batch may correspond to a defined fraction of the
       production. The batch size can be defined either by a fixed quantity or by the
       amount produced in a fixed time interval.

       Batch Number (or Lot Number)

       A unique combination of numbers, letters, and/or symbols that identifies a batch
       (or lot) and from which the production and distribution history can be determined.

       Bioburden

       The level and type (e.g. objectionable or not) of micro-organisms that can be
       present in raw materials, API starting materials, intermediates or APIs. Bioburden
       should not be considered contamination unless the levels have been exceeded
       or defined objectionable organisms have been detected.

       Calibration

       The demonstration that a particular instrument or device produces results within
       specified limits by comparison with those produced by a reference or traceable
       standard over an appropriate range of measurements.




 PE 009-17 (Part II)                      - 45 -                         25 August 2023
                                                                               Glossary



      Computer System

      A group of hardware components and associated software, designed and
      assembled to perform a specific function or group of functions.

      Computerized System

      A process or operation integrated with a computer system.

      Contamination

      The undesired introduction of impurities of a chemical or microbiological nature,
      or of foreign matter, into or onto a raw material, intermediate, or API during
      production, sampling, packaging or repackaging, storage or transport.

      Contract Manufacturer

      A manufacturer performing some aspect of manufacturing on behalf of the
      original manufacturer.

      Critical

      Describes a process step, process condition, test requirement, or other relevant
      parameter or item that must be controlled within predetermined criteria to ensure
      that the API meets its specification.

      Cross-Contamination

      Contamination of a material or product with another material or product.

      Deviation

      Departure from an approved instruction or established standard.

      Drug (Medicinal) Product

      The dosage form in the final immediate packaging intended for marketing.
      (Reference Q1A)

      Drug Substance

      See Active Pharmaceutical Ingredient

      Expiry Date (or Expiration Date)

      The date placed on the container/labels of an API designating the time during
      which the API is expected to remain within established shelf life specifications if
      stored under defined conditions, and after which it should not be used.




PE 009-17 (Part II)                      - 46 -                         25 August 2023
                                                                                   Glossary



      Impurity

      Any component present in the intermediate or API that is not the desired entity.

      Impurity Profile

      A description of the identified and unidentified impurities present in an API.

      In-Process Control (or Process Control)

      Checks performed during production in order to monitor and, if appropriate, to
      adjust the process and/or to ensure that the intermediate or API conforms to its
      specifications.

      Intermediate

      A material produced during steps of the processing of an API that undergoes
      further molecular change or purification before it becomes an API. Intermediates
      may or may not be isolated. (Note: this Guide only addresses those
      intermediates produced after the point that the company has defined as the point
      at which the production of the API begins.)

      Lot

      See Batch

      Lot Number see Batch Number

      See Batch Number

      Manufacture

      All operations of receipt of materials, production, packaging, repackaging,
      labelling, relabelling, quality control, release, storage, and distribution of APIs and
      related controls.

      Material

      A general term used to denote raw materials (starting materials, reagents,
      solvents), process aids, intermediates, APIs and packaging and labelling
      materials.

      Mother Liquor

      The residual liquid which remains after the crystallization or isolation processes.
      A mother liquor may contain unreacted materials, intermediates, levels of the API
      and/or impurities. It may be used for further processing.

      Packaging Material

      Any material intended to protect an intermediate or API during storage and
      transport.



PE 009-17 (Part II)                       - 47 -                            25 August 2023
                                                                                Glossary



      Procedure

      A documented description of the operations to be performed, the precautions to
      be taken and measures to be applied directly or indirectly related to the
      manufacture of an intermediate or API.

      Process Aids

      Materials, excluding solvents, used as an aid in the manufacture of an
      intermediate or API that do not themselves participate in a chemical or biological
      reaction (e.g. filter aid, activated carbon, etc).

      Process Control

      See In-Process Control

      Production

      All operations involved in the preparation of an API from receipt of materials
      through processing and packaging of the API.

      Qualification

      Action of proving and documenting that equipment or ancillary systems are
      properly installed, work correctly, and actually lead to the expected results.
      Qualification is part of validation, but the individual qualification steps alone do
      not constitute process validation.

      Quality Assurance (QA)

      The sum total of the organised arrangements made with the object of ensuring
      that all APIs are of the quality required for their intended use and that quality
      systems are maintained.

      Quality Control (QC)

      Checking or testing that specifications are met.

      Quality Unit(s)

      An organizational unit independent of production which fulfils both Quality
      Assurance and Quality Control responsibilities. This can be in the form of
      separate QA and QC units or a single individual or group, depending upon the
      size and structure of the organization.

      Quarantine

      The status of materials isolated physically or by other effective means pending a
      decision on their subsequent approval or rejection.




PE 009-17 (Part II)                      - 48 -                          25 August 2023
                                                                               Glossary



      Raw Material

      A general term used to denote starting materials, reagents, and solvents intended
      for use in the production of intermediates or APIs.

      Reference Standard, Primary

      A substance that has been shown by an extensive set of analytical tests to be
      authentic material that should be of high purity. This standard can be: (1)
      obtained from an officially recognised source, or (2) prepared by independent
      synthesis, or (3) obtained from existing production material of high purity, or (4)
      prepared by further purification of existing production material.

      Reference Standard, Secondary

      A substance of established quality and purity, as shown by comparison to a
      primary reference standard, used as a reference standard for routine laboratory
      analysis.

      Reprocessing

      Introducing an intermediate or API, including one that does not conform to
      standards or specifications, back into the process and repeating a crystallization
      step or other appropriate chemical or physical manipulation steps (e.g.,
      distillation, filtration, chromatography, milling) that are part of the established
      manufacturing process. Continuation of a process step after an in-process
      control test has shown that the step is incomplete is considered to be part of the
      normal process, and not reprocessing.

      Retest Date

      The date when a material should be re-examined to ensure that it is still suitable
      for use.

      Reworking

      Subjecting an intermediate or API that does not conform to standards or
      specifications to one or more processing steps that are different from the
      established manufacturing process to obtain acceptable quality intermediate or
      API (e.g., recrystallizing with a different solvent).

      Signature (signed)

      See definition for signed

      Signed (signature)

      The record of the individual who performed a particular action or review. This
      record can be initials, full handwritten signature, personal seal, or authenticated
      and secure electronic signature.




PE 009-17 (Part II)                      - 49 -                         25 August 2023
                                                                                    Glossary



      Solvent

      An inorganic or organic liquid used as a vehicle for the preparation of solutions
      or suspensions in the manufacture of an intermediate or API.

      Specification

      A list of tests, references to analytical procedures, and appropriate acceptance
      criteria that are numerical limits, ranges, or other criteria for the test described. It
      establishes the set of criteria to which a material should conform to be considered
      acceptable for its intended use. “Conformance to specification” means that the
      material, when tested according to the listed analytical procedures, will meet the
      listed acceptance criteria.

      Validation

      A documented program that provides a high degree of assurance that a specific
      process, method, or system will consistently produce a result meeting pre-
      determined acceptance criteria.

      Validation Protocol

      A written plan stating how validation will be conducted and defining acceptance
      criteria. For example, the protocol for a manufacturing process identifies
      processing equipment, critical process parameters/operating ranges, product
      characteristics, sampling, test data to be collected, number of validation runs, and
      acceptable test results.

      Yield, Expected

      The quantity of material or the percentage of theoretical yield anticipated at any
      appropriate phase of production based on previous laboratory, pilot scale, or
      manufacturing data.

      Yield, Theoretical

      The quantity that would be produced at any appropriate phase of production,
      based upon the quantity of material to be used, in the absence of any loss or error
      in actual production.




PE 009-17 (Part II)                        - 50 -                           25 August 2023
